

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): a study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023162
Article Type:	Protocol
Date Submitted by the Author:	24-Mar-2018
Complete List of Authors:	<p>Liu, Ying; The First Affiliated Hospital of Dalian Medical University Chen, Jilin; The First Affiliated Hospital of Dalian Medical University, Nephrology, Chen, Xiangmei; Chinese PLA General Hospital, Nephrology Sun, Xuefeng; Chinese PLA General Hospital, Nephrology Li, Wei; uwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Yang, Wang; uwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Sun, Ximing; Dalian University of Technology Wang, Degang; Dalian University of Technology Jiang, Hongli; The First Affiliated Hospital of Xi'an Jiaotong University Shi, Wei; Guangdong General Hospital, Guangdong Academy of Medical Sciences, Liu, Wenhui; Beijing Friendship Hospital Attached Capital Medical University, Department of Nephrology Fu, Ping; West China Hospital of Sichuan University Ding, X. Q.; Zhongshan Hospital, Fudan University, Chang, Ming; Dalian Municipal Central Hospital Liu, Shuxin; Dalian Municipal Central Hospital Yang, Xiao; The First Affiliated Hospital, Sun Yat-sen University Cao, Ning; General Hospital of Shenyang Military Region Chen, Menghua; General Hospital of Ningxia Medical University Ni, Zhao-Hui; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chen, Jing; Huashan Hospital, Fudan University Sun, Shiren; The Fourth Military Medical University Wang, Huimin; General Hospital of Benxi Iron and Steel Co., Ltd. He, Yani; Daping Hospital Affiliated to Army Military Medical University Gao, Bihu; Affiliated Zhong Shan Hospital of Dalian University, Wang, Jianqin; Lanzhou University Second Hospital Hao, Lirong; the First Affiliated Hospital of Harbin Medical University, Liu, Jian; The First Affiliated Hospital of Xinjiang Medical University He, Qiang; Zhejiang Provincial People's Hospital Liu, Hongmei; An Steel Group Hospital Yi, Na; An Steel Group Hospital Shao, Fengmin; The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital Jiao, Jundong; The Second Affiliated Hospital of Harbin Medical</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>University Ma, Yuhuan; General Hospital of Mining Industry Group FuXin Yao, Li; The First Hospital of China Medical University Sun, Yi; General Hospital Affiliated To Shenyang Medical College Li, Detian; Shengjing Hospital of China Medical University Szczech, Lynda; FibroGen, Inc Fang, Ming; the First Affiliated Hospital of Dalian Medical University Odeh, Zach; Dalian Medical University Graduate School Lin, Hongli; The First Affiliated Hospital of Dalian Medical University , Kidney Disease Research Institute, Department of nephrology</p>
<p>Keywords:</p>	<p>End-Stage Renal Disease, Hemodialysis, Timing of Dialysis Initiation, Fuzzy mathematics, Estimate Glomerular Filtration Rate</p>



1
2
3 **Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): a**
4 **study protocol for a randomised controlled trial**
5
6
7

8 Ying Liu, MD^{1,2,&}, Jilin Chen, MD^{1,2,&}, Xiangmei Chen, MD, PhD³, Xuefeng Sun,
9 MD, PhD³, Wei Li, PhD⁴, Yang Wang, MPH⁴, Ximing Sun⁵, Degang Wang⁵, Hongli
10 Jiang, MD⁶, Wei Shi, MD, PhD⁷, Wenhui Liu, MD, PhD⁸, Ping Fu, MD, PhD⁹,
11 Xiaoqiang Ding, MD, PhD¹⁰, Ming Chang, MM¹¹, Shuxin Liu, PhD¹¹, Xiao Yang,
12 MD, PhD¹², Ning Cao, PhD¹³, Menghua Chen, PhD¹⁴, Zhaohui Ni, MD, PhD¹⁵, Jing
13 Cheng, MD, PhD¹⁶, Shiren Sun, MD, PhD¹⁷, Huimin Wang, MM¹⁸, Yani He, MD,
14 PhD¹⁹, Bihu Gao, PhD²⁰, Jianqin Wang, PhD²¹, Lirong Hao, MD, PhD²², Jian Liu,
15 MD, PhD²³, Qiang He, PhD²⁴, Hongmei Liu, MM²⁵, Na Yi, MM²⁵, Fengmin Shao,
16 PhD²⁶, Jundong Jiao, MD, PhD²⁷, Yuhuan Ma, MM²⁸, Li Yao, MD, PhD²⁹, Yi Sun,
17 MD, PhD³⁰, Detian Li, MD, PhD³¹, Lynda Szczech, MD, MSCE³², Ming Fang, MD²,
18 Zach Odeh, MS¹, Hongli Lin, MD, PhD^{2,*}
19
20
21
22
23
24
25
26
27
28

29
30
31 ¹ Dalian Medical University Graduate School, Dalian, China

32 ² Kidney Disease Research Institute, Department of Nephrology, the First Affiliated
33 Hospital of Dalian Medical University, Dalian, China

34 ³ Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute
35 of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research
36 Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research,
37 Beijing, China

38 ⁴ Medical Research & Biometrics Center, Fuwai Hospital, National Center for
39 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union
40 Medical College, Beijing, China

41 ⁵ School of Control Science and Engineering, Dalian University of Technology,
42 Dalian, China

43 ⁶ Blood Purification Center, The First Affiliated Hospital of Xi'an Jiaotong University,
44 Xi'an, China

45 ⁷ Division of Nephrology, Guangdong General Hospital, Guangdong Academy of
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Medical Sciences, Guangzhou, China.

4
5 ⁸ Division of Nephrology, Beijing Friendship Hospital, Capital Medical University,
6
7 Beijing, China

8
9 ⁹ Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan
10
11 University, Chengdu, China

12
13 ¹⁰ Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China

14
15 ¹¹ Division of Nephrology, Dalian Municipal Central Hospital, Dalian, China

16
17 ¹² Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University,
18
19 Key Laboratory of Nephrology, Ministry of Health of China, Guangzhou, China

20
21 ¹³ Blood Purification Center, General Hospital of Shenyang Military Region,
22
23 Shenyang, China

24
25 ¹⁴ Department of Nephrology, General Hospital of Ningxia Medical University,
26
27 Yinchuan, China

28
29 ¹⁵ Department of Nephrology, Renji Hospital Affiliated to Shanghai Jiaotong
30
31 University Medical School, Shanghai, China

32
33 ¹⁶ Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China

34
35 ¹⁷ Department of Nephrology, Xijing Hospital, The Fourth Military Medical
36
37 University, Xi'an, China

38
39 ¹⁸ Division of Nephrology, General Hospital of Benxi Iron and Steel Co., Ltd., Benxi,
40
41 China

42
43 ¹⁹ Blood Purification Center, Daping Hospital Affiliated to Army Military Medical
44
45 University, Chongqing, China

46
47 ²⁰ Division of Nephrology, Affiliated Zhong Shan Hospital of Dalian University,
48
49 Dalian, China

50
51 ²¹ Division of Nephrology, Lanzhou University Second Hospital, Lanzhou, China

52
53 ²² Division of Nephrology, the First Affiliated Hospital of Harbin Medical University,
54
55 Harbin, China

56
57 ²³ Division of Nephrology, The First Affiliated Hospital of Xinjiang Medical
58
59 University, Urumchi, China

60
²⁴ Division of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou, China

1
2
3 ²⁵ Division of Nephrology, An Steel Group Hospital, Anshan, China

4
5 ²⁶ Blood Purification Center, The People's Hospital of Zhengzhou University &
6
7 Henan Provincial People's Hospital, Zhengzhou, China

8
9 ²⁷ Division of Nephrology, The Second Affiliated Hospital of Harbin Medical
10
11 University, Harbin, China

12
13 ²⁸ Division of Nephrology, General Hospital of Mining Industry Group FuXin, FuXin,
14
15 China

16
17 ²⁹ Division of Nephrology, The First Hospital of China Medical University, Shenyang,
18
19 China

20
21 ³⁰ Division of Nephrology, General Hospital Affiliated To Shenyang Medical College,
22
23 Shenyang, China

24
25 ³¹ Division of Nephrology, Shengjing Hospital of China Medical University,
26
27 Shenyang, China.

28
29 ³² FibroGen, Inc., San Francisco, CA, USA.

30
31 &These authors contributed equally to this work and should be considered co-first
32
33 authors

34
35 *Corresponding Author: Hongli Lin, Kidney Disease Research Institute, Department
36
37 of nephrology, the First Affiliated Hospital of Dalian Medical University, No. 222,
38
39 Zhongshan Road, Dalian 116011, China. Telephone: +86041183636963-3537. E-mail:
40
41 hllin@dlmedu.edu.cn

42
43 The word count of the article: 3163 words

44 **Abstract**

45
46 **Introduction** Starting dialysis early and late results in a lower quality of life and a
47
48 poor prognosis in hemodialysis patients. However, there remains no consensus on the
49
50 optimal timing of dialysis initiation mainly due to the lack of suitable methods to
51
52 assess variations in dialysis start times. We established a novel equation named DIFE
53
54 (Dialysis Initiation based on Fuzzy-mathematics Equation) through a previous
55
56 retrospective multicenter clinical cohort study in mainland China. The parameters of
57
58 the DIFE include nine biochemical markers and clinical variables altogether influence
59
60 dialysis initiation. To verify the external validity and clinical accuracy of DIFE, we

1
2
3 designed the ADIFE (assessment of DIFE) study with a prospective, multicenter,
4 randomized controlled, open-label trial to assess the clinical outcomes between
5 patients who initiate dialysis in an optimal start dialysis group and a late start dialysis
6 group based on DIFE.
7
8
9

10 **Methods and analysis** A total of 496 enrolled end-stage renal disease (ESRD)
11 subjects will be randomised 1:1 to the optimal start dialysis group with DIFE value
12 between 30 and 35 or late start dialysis group with DIFE value less than 30 using the
13 Randomization and Trial Supply Management (RTSM) system. Participants will be
14 assessed with signs and symptoms change, dialysis mode and parameters, biochemical
15 and inflammatory markers, Subjective Global Assessment (SGA), Kidney Disease
16 Quality of Life Short Form (KDQOL-SFTM), Cognitive Assessment (MoCA), Medical
17 costs, adverse events, and concomitant medication at baseline, pre-dialysis visiting
18 stage and post-dialysis visiting stage every 12 to 24 weeks. The following data were
19 recorded on standardized online electronic case report forms (eCRFs). The primary
20 endpoints include all-cause and cerebro-cardiovascular mortality. The secondary
21 endpoints include non-fatal cerebro-cardiovascular events, annual hospitalization rate,
22 quality of life, medical costs, and hemodialysis related complications.
23
24
25
26
27
28
29
30
31
32
33

34 **Ethics and dissemination** The study was approved on 31 October 2017 by the Ethics
35 Committee of the First Affiliated Hospital of Dalian Medical University China
36 (Registration No: YJ-KY-2017-119). We aim to present the final results of the ADIFE
37 trial in peer-reviewed journals, Clinical Practice Guideline and at scientific meetings
38 within 3 years after the start of the recruitment.
39
40
41
42

43 **Trial registration number:** ClinicalTrial.gov. NCT03385902; Pre-results.

44 **Keywords** End-Stage Renal Disease; Hemodialysis; Timing of Dialysis Initiation;
45 Fuzzy mathematics.
46
47
48

49 **Strengths and limitations of this study**

50
51 ► We established a novel and quantifiable equation, named DIFE, which contains
52 nine laboratory and clinical parameters together that influence the timing of dialysis
53 initiation by a retrospective cohort study, which we found a significant advantages of
54 the DIFE for assessing the timing of dialysis initiation than estimate glomerular
55
56
57
58
59
60

1
2
3 filtration rate (eGFR) alone.

4
5 ▶ This is the first prospective randomized controlled study to assess the timing for
6 initiation of dialysis based on DIFE in patients with ESRD.

7
8 ▶ The study will provide acceptability and feasibility data for optimal dialysis
9 initiation based on DIFE avoiding early and late start dialysis in ESRD patients.

10
11 ▶ limitations: All participants will be recruited from 28 hemodialysis centers in
12 mainland china which may be associated with sample selection bias.

13
14 ▶ limitations: there is no uniform dialyzer across all hemodialysis centers during
15 dialysis treatment of participants.

16 17 18 19 **Introduction**

20
21 The growing prevalence and incidence rate of ESRD is a global challenge¹.
22 Hemodialysis is the main treatment for patients with ESRD, and its start time has a
23 significant effect on the survival patients with ESRD²⁻⁴. Late and early start for
24 dialysis can negatively affect the quality of life and survival prognosis of patients, and
25 this sub-optimal timing results in economic burdens for families and society⁵⁻⁷.
26 Therefore, the optimal time to commence dialysis can improve a patient's quality of
27 life by relieving a patient's uremic symptoms, lowering the patient's risk of death, and
28 by reducing medical care costs⁴. However, there is still no consensus on the optimal
29 timing for ESRD patients to initiate dialysis, and it also remains uncertain whether the
30 early or late initiation of dialysis was associated with better outcomes. Several
31 observational studies found that earlier start of dialysis were associated with improved
32 survival and better prognosis^{5, 8, 9}. However, some cohort studies and a randomized
33 controlled trial of the Initiating Dialysis Early and Late (IDEAL) study have shown
34 that patients with early initiation of dialysis were associated with a poor survival and
35 that late initiation of dialysis had a lower risk of mortality and improved survival¹⁰⁻¹³.
36 These aforementioned findings are controversial mainly due to inefficient or outdated
37 methods for assessing dialysis timing. All of the above studies used the
38 creatinine-based estimate glomerular filtration rate (eGFR), a value whose specificity
39 is affected by nutritional status and muscle mass, calculated by either the Modified
40 Diet in Renal Disease equation or the Cockcroft-Gault equation^{14, 15}. Studies showed

1
2
3 that some clinical factors such as old age, volume overload, malnutrition, diabetes,
4 and heart failure strongly influenced the timing of dialysis initiation^{5, 16-18}. Therefore,
5 Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for
6 Hemodialysis Adequacy recommend that the decision to initiation maintenance
7 dialysis should be based primarily on assessment of specific complications of kidney
8 disease, including signs and symptoms of uremia, protein-energy wasting, metabolic
9 abnormalities, and volume overload, rather than based on the eGFR alone^{19, 20}. The
10 deviation from an empirical decision to an assessment of varying clinical conditions
11 inevitably leads to a lack of consensus due to the doctor's subjective judgements,
12 which can lead to a sub-optimal decision of early or late initiation of dialysis.
13
14
15
16
17
18
19
20

21 Thus, the research team established a novel equation of timing of dialysis
22 initiation based on a Fuzzy mathematical method (DIFE) derived from a previous
23 multicenter retrospective cohort study with large-scale samples. The DIFE includes 9
24 parameters of sex, age, blood urea nitrogen, serum creatinine, hemoglobin, albumin,
25 serum phosphorus, heart failure condition, and diabetes condition which
26 effectively combines subjective clinical variables with objective biochemical markers
27 for dialysis initiation decision making. The DIFE study showed that the 3 years
28 dialysis mortality of patients in the optimal start group (DIFE between 30 to 35) was
29 9.9 % significantly lower than the late start group (DIFE less than 30) of 19.2%.
30 Moreover, ROC curve analysis indicated that the area under ROC (AUROC) of
31 prediction of 3 years death in hemodialysis initiation assessed by the DIFE was
32 significantly higher than that by eGFR (0.73 versus 0.55, $p < 0.01$). Therefore, the
33 DIFE was more accurate and effective for assessing the timing of dialysis initiation
34 than eGFR alone. Furthermore, the DIFE equation was convenient for popularization
35 and application owing to transforming the subjective clinical factors into objective
36 parameters, especially for non-nephrologist and doctors in primary hospitals. It may
37 be the new standard in the assessment of the timing of dialysis replacing eGFR.
38 To further evaluate the predictive ability and clinical accuracy of DIFE, we designed a
39 prospective multicenter randomized controlled trial from 28 hospitals located in
40 different regions in China to assess clinical outcomes of ESRD patients, placed in
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 optimal or late start dialysis cohorts on the basis of DIFE. The aims of the trial to
4 assess the effect of the optimal and late start dialysis, based on DIFE, using the 3
5 years mortality, hospitalization, morbidity, quality of life, and medical costs of
6 hemodialysis patients. The ADIFE study will provide clinical evidence for the optimal
7 time to start dialysis in ESRD patients based on DIFE.
8
9
10
11

12 **Methods and analysis**

13 **Study design**

14 The ADIFE study is a prospective, multicenter, randomized controlled, open-label
15 trial in ESRD patients. which was divided into an “optimal start dialysis” group with
16 DIFE value between 30 and 35 and a “late start dialysis” group with DIFE value less
17 than 30 respectively. The study will be implemented in 28 dialysis centers, covering
18 the seven administrative regions in China (North China, East China, South Central,
19 Northeast, Southwest and Northwest). Each participating center has systemic
20 follow-up for the participants with chronic kidney disease and can afford predialysis
21 care including preparation of vascular access in patients approaching hemodialysis.
22
23
24
25
26
27
28
29

30 Participants will be followed up at baseline, pre-dialysis visiting stage every 12
31 weeks, and post-dialysis visiting stage every 12 or 24 weeks. The whole trial flow
32 diagram is detailed in Figure 1. The protocol of ADIFE study was designed according
33 to the SPIRIT reporting guidelines²¹.
34
35
36
37

38 **Participants**

39 **Inclusion criteria**

40 Participants will enroll the study if they meet all the following requirements

- 41 a. Adults age between 18 to 75 years old;
 - 42 b. Chronic kidney disease with an eGFR (calculated by the CKD-EPI equation²²)
43 less than 15mL/min/1.73m² and the DIFE between 30 and 35;
 - 44 c. Expected to commence maintenance hemodialysis;
 - 45 d. Agreeable to randomization.
- 46
47
48
49
50
51
52

53 **Exclusion criteria**

54 Participants will be excluded if meet the one of the following items

- 55 a. Acute kidney injury (AKI) or AKI on chronic kidney diseases (CKD);
- 56
57
58
59
60

- b. With the primary disease of systemic lupus erythematosus (SLE) or systemic vasculitis;
- c. Have received or planning to receive a kidney transplant or peritoneal dialysis;
- d. Recently diagnosed cancer that was likely to impact on survival (except for cured cancer or remission for over 5 years, after radical resection of the basal cell carcinoma or squamous carcinoma of skin or carcinoma in-situ of any part of the body);
- e. Hepatocirrhosis;
- f. Positive test of Human Immunodeficiency Virus (HIV), the hepatitis B virus antigen (HBsAg) or anti-hepatitis C virus antibody (HCV Ab);
- g. Acute infection disease within 1 month;
- h. Bad habit which is difficult to withdrawal such as alcohol abuse;
- i. Poor compliance;
- j. Being pregnant, nursing or planing for pregnancy;
- k. Life expectancy less than 1 year;
- l. The investigator confirm that should not enroll in the study with any other cases.

Sample size considerations and Randomization

The sample size was calculated based on the results of DIFE study by retrospective cohort study, which showed the difference of the 3 years mortality rate between the optimal start dialysis group and late start dialysis group was 9.3%. As reported by the IDEAL study, the difference in the median time from randomization to the initiation of dialysis between the “early start” group and “late start” group was 5.6 months¹⁰. We assumed the time of dialysis initiation in the late start dialysis group would lag 6 months compared to the optimal start dialysis group. Therefore, the dialysis mortality rate of the late start dialysis group should be 2.5 years instead of 3 years. The power calculations using a a study-wide type I error rate (α) of 0.05, a type II error rate (β) of 0.2, and two-tailed statistical tests. The power analysis indicated that 225 participants would be required in each group. Allowing for an attrition rate of 10%, a total of 496 participants, or 248 in each group will be recruited.

After all 496 participants signed the informed consent form, the presence of the

1
2
3 inclusion criteria and the absence of the non-inclusion criteria was verified.
4
5 Randomization will be carried out centrally using the internet-based randomization
6
7 service (Randomization and Trial Supply Management system). Patients are stratified
8
9 by center, Enrolled patients are randomly assigned 1:1 to optimal start dialysis group
10
11 or late start dialysis group. Randomization allocation will be sent by automated email,
12
13 to the non-blind researcher performing the randomization using their unique user
14
15 name and password.

16 **Treatment**

17
18 All participants receive regular treatment as usual, which include regular dietary
19
20 advice, anemia and Chronic Kidney Disease-Mineral and Bone Disorder management,
21
22 blood pressure, and volume control as recommended by the KDIGO guideline and
23
24 Chinese Hemodialysis Adequacy guidelines^{19, 23-26}. Different types of vascular access
25
26 including temporary venous catheters, arteriovenous fistula, and artificial blood vessel
27
28 are permitted to be used in all participants. The use of such catheters is based only on
29
30 clinical requirements. Each participating center has been advised to consider early
31
32 access creation in each participant to avoid delay in the subsequent hemodialysis
33
34 treatment.

35
36 All participants undergoing hemodialysis treatment with capacity control dialysis
37
38 machine, bicarbonate dialysate, blood flow volume with 200 ~ 300ml/min, disposable
39
40 high-flux or low-flux dialyzer with membrane area 1.3 ~ 1.6m², dialysis dose is 4
41
42 hours per treatment with 2 or 3 times in one week; and the recommended spKt/V is
43
44 more than 1.2^{19, 26, 27}. However, despite the existence of dialysis management
45
46 guidelines in China, there is still potential for treatment variation between the
47
48 participating centers.

49 **Intervention**

50
51 Participants allocated to the ‘optimal start dialysis’ group will commence dialysis with
52
53 the DIFE values between 30 and 35. Participants allocated to the “late start dialysis”
54
55 group were monitored based on the changes in DIFE values in the pre-dialysis visiting
56
57 stage every 12 weeks until their DIFE values were less than 30, and then commenced
58
59 dialysis. Participants allocated to the “late start dialysis” group are able to commence
60

1
2
3 dialysis earlier based on the recommendation of their caring physician although the
4 DIFE no less than 30, for instance, Participants appearing obvious uremia symptoms,
5 volume overload, hyperkalaemia and so on, which the reasons for the early initiation
6 of dialysis to be recorded, this will allow for a subsequent analysis of actual DIFE at
7 the dialysis start time.
8
9
10
11

12 **Outcome measurement**

13
14 All enrolled participants will be followed up until death or until 144 weeks after
15 the last patient is randomized. Participants with “late start dialysis” group were
16 assessed every 12 weeks in the pre-dialysis visiting stage. During the period of
17 post-dialysis visiting stage, data will be collected every 12 weeks in the first year of
18 follow-up and every 24 weeks in the next two years of follow-up, The detailed
19 follow-up items in different visiting stage showed in table 1.
20
21
22
23
24

25 Comprehensive demographic data (age, gender, race, height, weight, education,
26 employment, etiology of ESRD, medical history, presence of comorbid conditions,
27 collected on all participants at baseline. Virology examination (Hepatitis B
28 Virus antigen, Hepatitis C virus antibody, Human immunodeficiency virus
29 antibody, syphilis antibody), urine human chorionic gonadotropin (HCG) were tested
30 in screening stage, Vital signs, which include temperature (T), heart rate (HR),
31 respiratory rate (RR), non-invasive blood pressure (BP) were monitored each
32 follow-up. Biochemical indexes including blood cell count (Red Blood Cells, White
33 Blood Cells, Platelets), hemoglobin (Hb), blood urea nitrogen (BUN),
34 serum creatinine (Scr), eGFR, electrolytes (serum sodium, serum potassium, serum
35 chloride, serum calcium, serum phosphate), alanine transaminase (ALT),
36 glutamic-oxalacetic transaminase (AST), total bilirubin (T-BIL), blood glucose,
37 serum lipid, serum ferritin (SF), parathyroid hormone (PTH), and ferritin were tested
38 every 12-24 weeks in each participating center. Inflammatory biomarkers including
39 high-sensitivity C-reactive protein (hs-CRP), IL-6, IL-10, TNF- α and
40 β_2 -microglobulin (β_2 -MG) will be collected and tested every 24 weeks by central lab in
41 the Kidney Disease Research Institute of Dalian Medical University. Nutritional status
42 was assessed using Subjective Global Assessment (SGA)²⁸ and serum albumin level
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

every 24 weeks. Quality of life will be measured using the well-validated Kidney Disease Quality of Life Short Form™ (KDQOL-SF™)^{29, 30} every 48 weeks; and cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA)³¹ every 24 weeks. Concomitant medications including calcium channel blockers (CCB), statins, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and erythropoiesis stimulating agents (ESAs) are also being collected at baseline and follow-up period. Medical costs will be recorded in pre-dialysis visiting stage and post-dialysis visiting stage by both the questionnaire and medical insurance records of the participants, including dialysis related costs, hospitalization related costs, and outpatient costs of comorbidities treatment.

The all following data will be recorded on standardized online electronic case report forms (eCRFs) based on electronic data acquisition system. All adverse events (AE) will be recorded on the eCRFs on specific pages reserved for this purpose. Serious adverse events (SAE) are defined as death, life-threatening, hospitalization (or prolongation of initial hospitalization), cause disability or cause permanent damage, a congenital anomaly, or birth defect. Completed eCRFs entered into a secured central database for independent quality control and centralized analysis.

Table 1 The Follow-up items in different visiting stage of ADIFE study

Follow-up items	Screening stage	Pre-dialysis visiting stage	Post-dialysis visiting stage
			V0~V8 (0~144w)
Signed informed consent form	√	-	-
Inclusion and exclusion criteria	√	-	-
Demographic data	√	-	-
Vital signs, physical examination	√	√	√ (V0~V8)
Urine HCG	√	-	-
Virology examination	√	-	-
Blood routine test	√	√	√ (V0~V8)
BUN, Scr, eGFR, Alb, Electrolytes,	√	√	√ (V0~V8)
ALT, AST, T-BIL, Blood glucose,	-	-	√ (V0, V4, V6, V8)

Serum lipid, serum Ferrium			
PTH, Ferritin	-	-	√ (V0, V2, V4~V8)
Hs-CRP, IL-6, IL-10, TNF-α, β ₂ -MG	-	-	√ (V0, V2, V4~V8)
KDQoL-SF	-	-	√ (V0, V4, V6, V8)
MoCA	-	-	√ (V0, V2, V4~V8)
SGA	-	-	√ (V0, V2, V4~V8)
Vascular access	-	-	√ (V0~V8)
Medical costs	-	√	√ (V0~V8)
Complications related to dialysis	-	-	√ (V0~V8)
AE, SAE	-	√	√ (V0~V8)
Concomitant medications	-	√	√ (V0~V8)

Note: “√” represent selected follow-up items; “-” represent not-selected follow-up items.

Endpoint measurements

The primary endpoints measure is all-cause mortality and cerebro-cardiovascular mortality within 3 years following randomization to “optimal start dialysis” or “late start dialysis” groups. Cerebro-cardiovascular mortality includes the deaths caused by myocardial infarction, stroke, heart failure, or arrhythmia. Secondary endpoints include cerebro-cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, transient ischemic attack, new-onset angina, acute heart failure or severe arrhythmia which should to be hospitalized), infectious complications, hemodialysis complications (including changes of vascular access, vascular access related infection, fluid and electrolyte disorders, and cognitive dysfunction), annual hospitalization (proportion of participants admitted to hospital every year), quality of life, nutrition assessment, cognitive dysfunction, and medical costs.

Statistical analysis

Qualitative variables will be described as number and percentage, and quantitative variables as number, mean, and standard deviation. Quantitative variables with skewed distributions will be presented as median and interquartile range (25th percentile to 75th percentile). Survival analysis will be on an intention-to-treat basis (“optimal start dialysis” vs “late start dialysis” based on the randomization allocation), Data will be censored for participants that do not reach the endpoint. The

1
2
3 characteristics of the two groups will be compared using the usual univariate tests
4 (chi-squared or Fisher's exact test for categorical variables, and Student's unpaired
5 t-test or the Wilcoxon rank-sum test for quantitative variables, as appropriate). The
6 primary outcome will be analyzed by an unadjusted COX proportional hazards model,
7 with secondary analysis by the Kaplan-Meier survival analysis. The comparison of the
8 secondary outcomes will be the same as the baseline characteristics tests. SALL
9 analyses will be performed using SAS Version 9.2 (SAS Institute Inc, Cary, NC, USA)
10 by the team of statisticians at the Fuwai Hospital, China. The significance level is set
11 at 0.05 for all final analyses.
12
13

14 **Ethics and dissemination**

15 **Ethics**

16 The study protocol was approved by the ethics committees of the First Affiliated
17 Hospital of Dalian Medical University (YJ-KY-2017-119), and all participating
18 centers will obtain additional ethics approval in accordance with local practice.
19

20 **Informed consent and withdrawal from the study**

21 Each participant or authorised surrogates will sign an informed consent form. The
22 process of informed consent will be in accordance with the Declaration of Helsinki.
23 Participants were fully informed about the ADIFE study by the investigators; and
24 were able to discuss the trial process with their nephrologists and contact the
25 investigator directly to request further information. participants and authorised
26 surrogates will received the related materials of informed consent. Participants were
27 informed of their right to withdraw at any time without their care being affected in
28 any way.
29

30 **Dissemination plan**

31 Survey data will be exported directly from eCRF as a text file and imported in
32 electronic form for scoring and analysis using statistics software. A detailed database
33 will track participants' progress through the trial including the scheduling of
34 assessments and reminders to complete assessments. Detailed strategies, including
35 phone or text message reminders will be used to remind participants about upcoming
36 assessments. All members of the research team and other associated personnel will
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 have access to the final trial dataset in both identified and re-identifiable forms.
4

5 Print data will be stored in locked filing cabinets accessible only to the research
6 team. Electronic data will be stored on password-protected computers or servers only
7 accessible to the research team. All paper and electronic records will be retained and
8 disposed of in accordance with the requirements of the Criteria for
9 the Quality Control of Clinical Trials from the China Food and Drug Administration
10 (CFDA).
11
12
13
14
15

16 Results from the outcome measures will not be presented in a way that adversely
17 affects the confidentiality of participants. The description of participants will not
18 allow identification of individual participants, and individual results and individual
19 names will not be revealed. Final reports and publications will only consist of
20 aggregated results. At the completion of the study, participants will receive a plain
21 Chinese summary of study results. Scientific reports of the main outcomes, secondary
22 outcomes and process evaluation will be submitted to an international peer-reviewed
23 journal. Results will also be presented at national and international conferences
24 relevant to the subject fields.
25
26
27
28
29
30
31

32 **Data management**

33 All information of participants will be recorded on standardized online electronic case
34 report forms (eCRFs) which will be anonymized and saved on password-protected
35 computers. The data monitoring committee (DMC) is independent from the sponsor
36 and competing interests, will meet twice yearly to review the efficacy and safety data.
37
38
39
40
41

42 **Oversight committees**

43 A Trial Steering Committee has been set-up and will include an independent chairman,
44 28 independent members and the study's investigators.
45
46

47 **Safety monitoring**

48 AE will be closely monitored. These are events that are likely to affect to a significant
49 degree the safety or physical or mental integrity of the participants in the trial. SAE
50 must be reported to the sponsor (First Affiliated Hospital of Dalian Medical
51 University, China) and the State Food and Drug Administration promptly by fax or
52 telephone by investigators, followed by a written report within 24 hours. The sponsor
53
54
55
56
57
58
59
60

1
2
3 will be notified immediately of any case where the above definition applies during the
4 trial.
5

6 **Discussion**

7
8 The timing of dialysis initiation is a risk factor affecting the prognosis of patients with
9 ESRD. Optimal timing of dialysis initiation remains unclear. Some studies showed
10 early start dialysis was associated with a lower risk of mortality⁵ and others
11 studies indicated either a survival advantage of late start dialysis^{3, 11, 12, 32} or
12 comparable mortality risk between early and late start dialysis^{33, 34}. IDEAL study
13 indicated that using eGFR as the primary guide for when to start dialysis likely should
14 be abandoned in a patient with progressive advanced CKD¹⁰.
15
16
17
18
19
20

21 The novel DIFE integrate subjective clinical variables of uremic signs and
22 symptoms with objective biochemical markers beyond serum creatinine and eGFR for
23 assessing timing of dialysis initiation in ESRD patients, which provide a
24 individualized, effective and convenient tool for dialysis initiation decision making.
25 The results of ADIFE study will provide solid evidence for evaluating the accuracy
26 and efficacy of DIFE and maybe provide the potential optimal timing of dialysis
27 initiation with ESRD patients approaching the need for maintenance dialysis.
28
29
30
31
32
33

34 **Author Contributors**

35 All authors meet ICMJE criteria for authorship in that they have contributed
36 substantially to the conceptual design or the processes of data collection, analysis or
37 interpretation, the drafts and revisions of the study protocol and manuscript, granted
38 approval of the final version of the study protocol and acknowledged their
39 accountability with regard to the integrity and accuracy of this study protocol.
40
41
42
43
44

45 Research idea and study design: Hongli Lin, Xiangmei Chen and Xuefeng Sun.

46 Writing and reviewing of the protocol: Jilin chen, Ying Liu, Hongli Lin and Yang
47 Wang.
48

49 Drafting of the manuscript: Jilin chen and Ying Liu will be responsible for
50 administrative and managerial procedures related to all phases of the trial, which will
51 be supervised by Hongli Lin.
52
53
54

55 Statistical analysis: Yang Wang, and Wei Li.
56
57

Trial status

Recruitment will commence using digital social media networks and print-based advertising nationwide in April 2018. Completion of recruitment is expected in December 2018. The study will be completed in December 2021.

Acknowledgements

We acknowledge Dr. Mark Roger Marshall (Associate Professor of University of Auckland, New Zealand) for his helpful comments on the study design.

Funding

The ADIFE study is an investigator initiated and conducted study, This work was supported by the special fund for National Health and Family Planning Commission (NHFPC) Scientific Research in the Public Welfare. Grant number is 201502023.

The NHFPC had no role in the design, conduct, management, analysis, or interpretation of the study.

Conflicts of interests None declared.

References


- 1 Woo KT, Choong HL, Wong KS, Tan HB, Chan CM. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. *Kidney international*. 2012; **81**: 1044-5.
- 2 Feng L, Jin AZ, Allen JC, Chow KY, Jafar TH. Timing of commencement of maintenance dialysis and mortality in young and older adults in Singapore. *BMC nephrology*. 2017; **18**: 176.
- 3 Park JY, Yoo KD, Kim YC, Kim DK, Joo KW, Kang SW, *et al*. Early dialysis initiation does not improve clinical outcomes in elderly end-stage renal disease patients: A multicenter prospective cohort study. *PloS one*. 2017; **12**: e0175830.
- 4 Mehrotra R, Rivara M, Himmelfarb J. Initiation of dialysis should be timely: neither early nor late. *Seminars in dialysis*. 2013; **26**: 644-9.
- 5 Churchill DN. An evidence-based approach to earlier initiation of dialysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 1997; **30**: 899-906.
- 6 Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. *Journal of the American Society of Nephrology : JASN*. 2002; **13**: 2125-32.
- 7 Faust J, Schreiner O. Early versus late initiation of dialysis. *The New England journal of medicine*. 2010; **363**: 2368-9; author reply 69-70.
- 8 Wingard RL, Pupim LB, Krishnan M, Shintani A, Ikizler TA, Hakim RM. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. *Clinical journal of the American Society of Nephrology : CJASN*. 2007; **2**: 1170-5.
- 9 Korevaar JC, Jansen MA, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, *et al*. When to initiate dialysis: effect of proposed US guidelines on survival. *Lancet*. 2001; **358**: 1046-50.
- 10 Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, *et al*. A randomized, controlled

- 1
2
3 trial of early versus late initiation of dialysis. *The New England journal of medicine*. 2010; **363**: 609-19.
- 4 11 Wright S, Klausner D, Baird B, Williams ME, Steinman T, Tang H, *et al*. Timing of dialysis initiation
5 and survival in ESRD. *Clinical journal of the American Society of Nephrology : CJASN*. 2010; **5**: 1828-35.
- 6 12 Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC, Taiwan Society of N. Impact of the clinical
7 conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study
8 in Taiwan. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and
9 Transplant Association - European Renal Association*. 2010; **25**: 2616-24.
- 10 13 Susantitaphong P, Altamimi S, Ashkar M, Balk EM, Stel VS, Wright S, *et al*. GFR at initiation of
11 dialysis and mortality in CKD: a meta-analysis. *American journal of kidney diseases : the official journal
12 of the National Kidney Foundation*. 2012; **59**: 829-40.
- 13 14 Zaman T, Filipowicz R, Beddhu S. Implications and importance of skeletal muscle mass in
14 estimating glomerular filtration rate at dialysis initiation. *Journal of renal nutrition : the official journal
15 of the Council on Renal Nutrition of the National Kidney Foundation*. 2013; **23**: 233-6.
- 16 15 Escoli R, Luz I, Santos P, Vila Lobos A. Glomerular Filtration Rate and Initiation of Dialysis.
17 *Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for
18 Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2017; **21**:
19 606-10.
- 20 16 Lin X, Zeng XZ, Ai J. The Glomerular Filtration Rate (GFR) at Dialysis Initiation and Mortality in
21 Chronic Kidney Disease (CKD) in East Asian Populations: A Meta-analysis. *Internal medicine*. 2016; **55**:
22 3097-104.
- 23 17 Lassalle M, Labeeuw M, Frimat L, Villar E, Joyeux V, Couchoud C, *et al*. Age and comorbidity may
24 explain the paradoxical association of an early dialysis start with poor survival. *Kidney international*.
25 2010; **77**: 700-7.
- 26 18 Wang AY, Woo J. Early versus late initiation of dialysis and nutrition: does a transition mean a
27 change in dietary protein intake? *Journal of renal nutrition : the official journal of the Council on Renal
28 Nutrition of the National Kidney Foundation*. 2013; **23**: 228-32.
- 29 19 National Kidney F. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update.
30 *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2015; **66**:
31 884-930.
- 32 20 Grootendorst DC, Michels WM, Richardson JD, Jager KJ, Boeschoten EW, Dekker FW, *et al*. The
33 MDRD formula does not reflect GFR in ESRD patients. *Nephrology, dialysis, transplantation : official
34 publication of the European Dialysis and Transplant Association - European Renal Association*. 2011;
35 **26**: 1932-7.
- 36 21 Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle AJK, *et al*. SPIRIT 2013 Statement:
37 defining standard protocol items for clinical trials. *Revista panamericana de salud publica = Pan
38 American journal of public health*. 2015; **38**: 506-14.
- 39 22 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, *et al*. A new equation to
40 estimate glomerular filtration rate. *Annals of internal medicine*. 2009; **150**: 604-12.
- 41 23 Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, *et al*. KDOQI US commentary on
42 the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. *American
43 journal of kidney diseases : the official journal of the National Kidney Foundation*. 2013; **62**: 201-13.
- 44 24 Klinger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, *et al*. KDOQI US commentary
45 on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *American journal of kidney diseases :
46 the official journal of the National Kidney Foundation*. 2013; **62**: 849-59.

- 1
2
3 25 Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, *et al.* KDOQI US
4 Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation,
5 Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
6 *American journal of kidney diseases : the official journal of the National Kidney Foundation.* 2017; **70**:
7 737-51.
8
9 26 中国医师协会肾脏病医师分会血液透析充分性协作组. 中国血液透析充分性临床实践指南.
10 *中华医学杂志.* 2015; **95**: 2748-53.
11
12 27 陈香美, 丁小强, 刘伏友, 刘志红, 陈江华. 血液净化标准操作规程:2010 版. 2010.
13
14 28 Raguso CA, Maisonneuve N, Pichard C. [Subjective Global Assessment (SGA): evaluation and
15 followup of nutritional state]. *Revue medicale de la Suisse romande.* 2004; **124**: 607-10.
16
17 29 Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality
18 of life (KDQOL) instrument. *Qual Life Res.* 1994; **3**: 329-38.
19
20 30 Hays RD KJ, Mapes D, Coons S, Amin N, Carter WB, Kamberg C. Kidney Disease Quality of Life
21 Short Form (KDQOL-SF™), Version 1.3: A Manual for Use and Scoring. .
22
23 31 Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, *et al.* The Montreal
24 Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the*
25 *American Geriatrics Society.* 2005; **53**: 695-9.
26
27 32 Pan Y, Xu XD, Guo LL, Cai LL, Jin HM. Association of early versus late initiation of dialysis with
28 mortality: systematic review and meta-analysis. *Nephron Clinical practice.* 2012; **120**: c121-31.
29
30 33 Yamagata K, Nakai S, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese
31 Society for Dialysis T. Late dialysis start did not affect long-term outcome in Japanese dialysis patients:
32 long-term prognosis from Japanese Society for [corrected] Dialysis Therapy Registry. *Therapeutic*
33 *apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the*
34 *Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.* 2012; **16**: 111-20.
35
36 34 Scialla JJ, Liu J, Crews DC, Guo H, Bandeen-Roche K, Ephraim PL, *et al.* An instrumental variable
37 approach finds no associated harm or benefit with early dialysis initiation in the United States. *Kidney*
38 *international.* 2014; **86**: 798-809.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial Flow Diagram



Trial Flow Diagram

451x254mm (72 x 72 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	#3	Date and version identifier	4
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1-3,15
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	16

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	,16
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	14
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5-6
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	5-6
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	6-7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	7-8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	9
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	9-10
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	9-10
8	adherence		and any procedures for monitoring adherence (eg, drug	
9			tablet return; laboratory tests)	
10				
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	9
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	10-11
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	Figure 1
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	8
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	15
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	9
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	9
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	n/a
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	13
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	13
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	13
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	12-13
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	12-13
52	analyses		adjusted analyses)	
53				
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	12-13
56	population and		adherence (eg, as randomised analysis), and any statistical	
57	missing data		methods to handle missing data (eg, multiple imputation)	
58				
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	14
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	13
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	14
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	13
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	13
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	14
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	16
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	13
60				

1		and disclosure of contractual agreements that limit such	
2		access for investigators	
3			
4	Ancillary and post	#30 Provisions, if any, for ancillary and post-trial care, and for	n/a
5	trial care	compensation to those who suffer harm from trial	
6		participation	
7			
8			
9	Dissemination policy:	#31a Plans for investigators and sponsor to communicate trial	14
10	trial results	results to participants, healthcare professionals, the public,	
11		and other relevant groups (eg, via publication, reporting in	
12		results databases, or other data sharing arrangements),	
13		including any publication restrictions	
14			
15			
16			
17	Dissemination policy:	#31b Authorship eligibility guidelines and any intended use of	n/a
18	authorship	professional writers	
19			
20			
21	Dissemination policy:	#31c Plans, if any, for granting public access to the full protocol,	n/a
22	reproducible	participant-level dataset, and statistical code	
23	research		
24			
25			
26			
27	Informed consent	#32 Model consent form and other related documentation given	13
28	materials	to participants and authorised surrogates	
29			
30			
31	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of	n/a
32		biological specimens for genetic or molecular analysis in the	
33		current trial and for future use in ancillary studies, if	
34		applicable	
35			
36			

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 38 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 39 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): a study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023162.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Oct-2018
Complete List of Authors:	<p>Liu, Ying; The First Affiliated Hospital of Dalian Medical University Chen, Jilin; The First Affiliated Hospital of Dalian Medical University, Nephrology, Chen, Xiangmei; Chinese PLA General Hospital, Nephrology Sun, Xuefeng; Chinese PLA General Hospital, Nephrology Li, Wei; Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Yang, Wang; Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Sun, Ximing; Dalian University of Technology Wang, Degang; Dalian University of Technology Jiang, Hongli; The First Affiliated Hospital of Xi'an Jiaotong University Shi, Wei; Guangdong General Hospital, Guangdong Academy of Medical Sciences, Liu, Wenhui; Beijing Friendship Hospital Attached Capital Medical University, Department of Nephrology Fu, Ping; West China Hospital of Sichuan University Ding, X. Q.; Zhongshan Hospital, Fudan University, Chang, Ming; Dalian Municipal Central Hospital Liu, Shuxin; Dalian Municipal Central Hospital Yang, Xiao; The First Affiliated Hospital, Sun Yat-sen University Cao, Ning; General Hospital of Shenyang Military Region Chen, Menghua; General Hospital of Ningxia Medical University Ni, Zhao-Hui; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chen, Jing; Huashan Hospital, Fudan University Sun, Shiren; The Fourth Military Medical University Liang, Xinling; Guangdong General Hospital Wang, Huimin; General Hospital of Benxi Iron and Steel Co., Ltd. He, Yani; Daping Hospital Affiliated to Army Military Medical University Gao, Bihu; Affiliated Zhong Shan Hospital of Dalian University, Wang, Jianqin; Lanzhou University Second Hospital Hao, Lirong; the First Affiliated Hospital of Harbin Medical University, Liu, Jian; The First Affiliated Hospital of Xinjiang Medical University Li, Suhua; The First Affiliated Hospital of Xinjiang Medical University He, Qiang; Zhejiang Provincial People's Hospital Liu, Hongmei; An Steel Group Hospital Yi, Na; An Steel Group Hospital Shao, Fengmin; The People's Hospital of Zhengzhou University & Henan</p>

	Provincial People's Hospital Jiao, Jundong; The Second Affiliated Hospital of Harbin Medical University Ma, Yuhuan; General Hospital of Mining Industry Group FuXin Yao, Li; The First Hospital of China Medical University Sun, Yi; General Hospital Affiliated To Shenyang Medical College Li, Detian; Shengjing Hospital of China Medical University Szczech, Lynda; FibroGen, Inc Fang, Ming; the First Affiliated Hospital of Dalian Medical University Odeh, Zach; Dalian Medical University Graduate School Lin, Hongli; The First Affiliated Hospital of Dalian Medical University , Kidney Disease Research Institute, Department of nephrology
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	End-Stage Renal Disease, Hemodialysis, Timing of Dialysis Initiation, Fuzzy mathematics

SCHOLARONE™
Manuscripts

1
2
3 **Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): a**
4 **study protocol for a randomised controlled trial**
5
6
7

8 Ying Liu, MD^{1,2,&}, Jilin Chen, MD^{1,2,&}, Xiangmei Chen, MD, PhD³, Xuefeng Sun,
9 MD, PhD³, Wei Li, PhD⁴, Yang Wang, MPH⁴, Ximing Sun⁵, Degang Wang⁵, Hongli
10 Jiang, MD⁶, Wei Shi, MD, PhD⁷, Wenhui Liu, MD, PhD⁸, Ping Fu, MD, PhD⁹,
11 Xiaoqiang Ding, MD, PhD¹⁰, Ming Chang, MM¹¹, Shuxin Liu, PhD¹¹, Xiao Yang,
12 MD, PhD¹², Ning Cao, PhD¹³, Menghua Chen, PhD¹⁴, Zhaohui Ni, MD, PhD¹⁵, Jing
13 Chen, MD, PhD¹⁶, Shiren Sun, MD, PhD¹⁷, Xinling Liang, MD, PhD⁷, Huimin Wang,
14 MM¹⁸, Yani He, MD, PhD¹⁹, Bihu Gao, PhD²⁰, Jianqin Wang, PhD²¹, Lirong Hao,
15 MD, PhD²², Jian Liu, MD, PhD²³, Suhua Li, MD²³, Qiang He, PhD²⁴, Hongmei Liu,
16 MM²⁵, Na Yi, MM²⁵, Fengmin Shao, PhD²⁶, Jundong Jiao, MD, PhD²⁷, Yuhuan Ma,
17 MM²⁸, Li Yao, MD, PhD²⁹, Yi Sun, MD, PhD³⁰, Detian Li, MD, PhD³¹, Lynda
18 Szczech, MD, MSCE³², Ming Fang, MD², Zach Odeh, MS¹, Hongli Lin, MD, PhD^{2,*}
19
20
21
22
23
24
25
26
27
28

29 ¹ Dalian Medical University Graduate School, Dalian, China

30 ² Kidney Disease Research Institute, Department of Nephrology, the First Affiliated
31 Hospital of Dalian Medical University, Dalian, China
32
33

34 ³ Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute
35 of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research
36 Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research,
37 Beijing, China
38
39
40

41 ⁴ Medical Research & Biometrics Center, Fuwai Hospital, National Center for
42 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union
43 Medical College, Beijing, China
44
45
46

47 ⁵ School of Control Science and Engineering, Dalian University of Technology,
48 Dalian, China
49
50

51 ⁶ Blood Purification Center, The First Affiliated Hospital of Xi'an Jiaotong University,
52 Xi'an, China
53

54 ⁷ Division of Nephrology, Guangdong General Hospital, Guangdong Academy of
55 Medical Sciences, Guangzhou, China.
56
57

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

⁸ Division of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

⁹ Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China

¹⁰ Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China

¹¹ Division of Nephrology, Dalian Municipal Central Hospital, Dalian, China

¹² Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Key Laboratory of Nephrology, Ministry of Health of China, Guangzhou, China

¹³ Blood Purification Center, General Hospital of Shenyang Military Region, Shenyang, China

¹⁴ Department of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, China

¹⁵ Department of Nephrology, Renji Hospital Affiliated to Shanghai Jiaotong University Medical School, Shanghai, China

¹⁶ Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China

¹⁷ Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China

¹⁸ Division of Nephrology, General Hospital of Benxi Iron and Steel Co., Ltd., Benxi, China

¹⁹ Blood Purification Center, Daping Hospital Affiliated to Army Military Medical University, Chongqing, China

²⁰ Division of Nephrology, Affiliated Zhong Shan Hospital of Dalian University, Dalian, China

²¹ Division of Nephrology, Lanzhou University Second Hospital, Lanzhou, China

²² Division of Nephrology, the First Affiliated Hospital of Harbin Medical University, Harbin, China

²³ Division of Nephrology, The First Affiliated Hospital of Xinjiang Medical University, Urumchi, China

²⁴ Division of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou, China

²⁵ Division of Nephrology, An Steel Group Hospital, Anshan, China

²⁶ Blood Purification Center, The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital, Zhengzhou, China

²⁷ Division of Nephrology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

²⁸ Division of Nephrology, General Hospital of Mining Industry Group FuXin, FuXin, China

²⁹ Division of Nephrology, The First Hospital of China Medical University, Shenyang, China

³⁰ Division of Nephrology, General Hospital Affiliated To Shenyang Medical College, Shenyang, China

³¹ Division of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.

³² FibroGen, Inc., San Francisco, CA, USA.

&These authors contributed equally to this work and should be considered co-first authors

*Corresponding Author: Hongli Lin, Kidney Disease Research Institute, Department of nephrology, the First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Dalian 116011, China. Telephone: +86041183636963-3537. E-mail: hllin@dlmedu.edu.cn

The word count of the article: 6613 words

Abstract

Introduction Starting dialysis early and late results in a lower quality of life and a poor prognosis in hemodialysis patients. However, there remains no consensus on the optimal timing of dialysis initiation mainly due to the lack of suitable methods to assess variations in dialysis start times. We established a novel equation named DIFE (Dialysis Initiation based on Fuzzy-mathematics Equation) through a previous retrospective multicenter clinical cohort study in mainland China. The parameters of the DIFE include nine biochemical markers and clinical variables altogether influence dialysis initiation. To verify the external validity and clinical accuracy of DIFE, we designed the ADIFE (assessment of DIFE) study with a prospective, multicenter,

1
2
3 randomized controlled, open-label trial to assess the clinical outcomes between
4 patients who initiate dialysis in an optimal start dialysis group and a late start dialysis
5 group based on DIFE.
6
7

8 **Methods and analysis** A total of 496 enrolled end-stage renal disease (ESRD)
9 subjects will be randomised 1:1 to the optimal start group with DIFE value between
10 30 and 35 or late start dialysis group with DIFE value less than 30 using the
11 Randomization and Trial Supply Management (RTSM) system. Participants will be
12 assessed with signs and symptoms change, dialysis mode and parameters, biochemical
13 and inflammatory markers, Subjective Global Assessment (SGA), Kidney Disease
14 Quality of Life Short Form (KDQOL-SFTM), Cognitive Assessment (MoCA), Medical
15 costs, adverse events, and concomitant medication at baseline, pre-dialysis visiting
16 stage and post-dialysis visiting stage every 12 to 24 weeks. The following data were
17 recorded on standardized online electronic case report forms (eCRFs). The primary
18 endpoints is all-cause mortality. The secondary endpoints include non-fatal
19 cerebro-cardiovascular events, annual hospitalization rate, quality of life, medical
20 costs, and hemodialysis related complications.
21
22

23 **Ethics and dissemination** Ethical approval was obtained from the Ethics Committee
24 of the First Affiliated Hospital of Dalian Medical University China (Registration No:
25 YJ-KY-2017-119).
26
27

28 The final results of the ADIFE trial will be presented to the study sponsor, clinical
29 researchers and patient and public involvement. Findings will be disseminated
30 through peer-reviewed journals, Clinical Practice Guideline and at scientific meetings.
31
32

33 **Trial registration number:** ClinicalTrial.gov. NCT03385902; Pre-results.
34
35

36 **Keywords** End-Stage Renal Disease; Hemodialysis; Timing of Dialysis Initiation;
37 Fuzzy mathematics.
38
39

40 **Strengths and limitations of this study**

41 ► We established a novel and quantifiable equation, named DIFE, which contains
42 nine laboratory and clinical parameters together that influence the timing of dialysis
43 initiation by a retrospective cohort study, which we found a significant advantages of
44 the DIFE for assessing the timing of dialysis initiation than estimate glomerular
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 filtration rate (eGFR) alone.

4
5 ▶ This is the first prospective randomized controlled study to assess the timing for
6 initiation of dialysis based on DIFE in patients with ESRD.

7
8 ▶ The study will provide acceptability and feasibility data for optimal dialysis
9 initiation based on DIFE avoiding early and late start dialysis in ESRD patients.

10
11 ▶ limitations: All participants will be recruited from 28 hemodialysis centers in
12 mainland china which may be associated with sample selection bias.

13
14 ▶ limitations: There is no uniform dialyzer across all hemodialysis centers during
15 dialysis treatment of participants.

16 17 18 19 20 **Introduction**

21 The growing prevalence and incidence rate of ESRD is a global challenge¹.
22 Hemodialysis is the main treatment for patients with ESRD, and its start time has a
23 significant effect on the survival patients with ESRD²⁻⁴. Late and early start for
24 dialysis can negatively affect the quality of life and survival prognosis of patients, and
25 this sub-optimal timing of dialysis results in economic burdens for families and
26 society⁵⁻⁷. Therefore, the optimal time to commence dialysis can improve a patient's
27 quality of life by relieving a patient's uremic symptoms, lowering the patient's
28 risk of death, and by reducing medical care costs⁴. However, there is still no
29 consensus on the optimal timing for ESRD patients to initiate dialysis, and it also
30 remains uncertain what is exactly optimal timing of dialysis was associated with
31 better outcomes. Several observational studies found that earlier start of dialysis were
32 associated with improved survival and better prognosis^{5, 8, 9}. However, some cohort
33 studies and a randomized controlled trial of the Initiating Dialysis Early and Late
34 (IDEAL) study have shown that patients with early initiation of dialysis were
35 associated with a poor survival and that late initiation of dialysis had a lower risk
36 of mortality and improved survival¹⁰⁻¹³. These aforementioned findings are
37 controversial mainly due to inefficient or outdated methods for assessing dialysis
38 timing. All of the above studies used the creatinine-based estimate glomerular
39 filtration rate (eGFR), a value whose specificity is affected by nutritional status and
40 muscle mass, calculated by either the Modified Diet in Renal Disease equation or the
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Cockcroft-Gault equation^{14, 15}. Studies showed that some clinical factors such as old
4 age, volume overload, malnutrition, diabetes, and heart failure strongly influenced the
5 timing of dialysis initiation^{5, 16-18}. Therefore, Kidney Disease Outcomes Quality
6 Initiative (KDOQI) Clinical Practice Guideline for Hemodialysis Adequacy
7 recommend that the decision to initiation maintenance dialysis should be based
8 primarily on assessment of specific complications of kidney disease, including signs
9 and symptoms of uremia, protein-energy wasting, metabolic abnormalities, and
10 volume overload, rather than based on the eGFR alone^{19, 20}. The deviation from an
11 empirical decision to an assessment of varying clinical conditions inevitably leads to a
12 lack of consensus due to the doctor's subjective judgements, which can lead to a
13 sub-optimal decision of early or late initiation of dialysis.
14
15

16
17
18
19
20
21
22
23 Thus, the research team established a novel equation of timing of dialysis
24 initiation based on a Fuzzy mathematical method (DIFE) derived from a previous
25 multicenter retrospective cohort study with large-scale samples. The DIFE includes 9
26 parameters of sex, age, blood urea nitrogen, serum creatinine, hemoglobin, albumin,
27 serum phosphorus, heart failure condition, and diabetes condition which
28 effectively combines subjective clinical variables with objective biochemical markers
29 for dialysis initiation decision making. The DIFE study showed that the 3 years
30 dialysis mortality of patients in the optimal start group (DIFE between 30 to 35) was
31 8.38% significantly lower than the late start group (DIFE less than 30) of 19.4%.
32 Moreover, ROC curve analysis indicated that the area under curve (AUC) of
33 prediction of 3 years death in dialysis initiation assessed by the DIFE was
34 significantly higher than that by eGFR (0.73 versus 0.55, $P < 0.01$). Therefore, the
35 DIFE was more accurate and effective for assessing the timing of he modialysis
36 initiation than eGFR alone. Furthermore, the DIFE equation was convenient
37 for popularization and application owing to transforming the subjective clinical
38 factors into objective parameters, especially for non-nephrologist and doctors in
39 primary hospitals. It may be the new standard in the assessment of the timing of
40 dialysis replacing eGFR. To further evaluate the predictive ability and clinical
41 accuracy of DIFE, we designed a prospective multicenter randomized controlled trial
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 from 28 hospitals located in different regions in China to assess clinical outcomes of
4 ESRD patients, placed in optimal or late start dialysis cohorts on the basis of DIFE.
5 The aims of the trial to assess the effect of the optimal and late start dialysis, based on
6 DIFE, using the 3 years mortality, hospitalization, morbidity, quality of life, and
7 medical costs of hemodialysis patients. The ADIFE study will provide clinical
8 evidence for the optimal time to start dialysis in ESRD patients based on DIFE.
9
10
11
12
13

14 **Methods and analysis**

15 **Study design**

16 The ADIFE study is a prospective, multicenter, randomized controlled, open-label
17 trial in ESRD patients, which was divided into an “optimal start dialysis” group with
18 DIFE value between 30 and 35 and a “late start dialysis” group with DIFE value less
19 than 30 respectively. The study will be implemented in 28 dialysis centers, covering
20 the seven administrative regions in China (North China, East China, South Central,
21 Northeast, Southwest and Northwest). Each participating center has systemic
22 follow-up for the participants with chronic kidney disease and can afford predialysis
23 care including preparation of vascular access in patients approaching hemodialysis.
24
25
26
27
28
29
30
31

32 Participants will be followed up at baseline, pre-dialysis visiting stage every 12
33 weeks, and post-dialysis visiting stage every 12 or 24 weeks. The whole trial flow
34 diagram is detailed in Figure 1. The protocol of ADIFE study was designed according
35 to the SPIRIT reporting guidelines²¹.
36
37
38
39

40 **Participants**

41 **Inclusion criteria**

42 Participants will enroll the study if they meet all the following requirements

- 43 a. Adults age between 18 to 75 years old;
 - 44 b. Chronic kidney disease with an eGFR (calculated by the CKD-EPI equation²²)
45 less than 15mL/min/1.73m² and the DIFE between 30 and 35;
 - 46 c. Expected to commence maintenance hemodialysis;
 - 47 d. Agreeable to randomization.
- 48
49
50
51
52
53

54 **Exclusion criteria**

55 Participants will be excluded if meet the one of the following items
56
57
58
59
60

- a. Acute kidney injury (AKI) or AKI on chronic kidney diseases (CKD);
- b. With the primary disease of systemic lupus erythematosus (SLE) or systemic vasculitis;
- c. Have received or planning to receive a kidney transplantation or peritoneal dialysis;
- d. Recently diagnosed cancer that was likely to impact on survival (except for cured cancer or remission for over 5 years, after radical resection of the basal cell carcinoma or squamous carcinoma of skin or carcinoma in-situ of any part of the body);
- e. Hepatocirrhosis;
- f. Positive test of Human Immunodeficiency Virus (HIV), the hepatitis B virus antigen (HBsAg) or anti-hepatitis C virus antibody (HCV Ab);
- g. Acute infection disease within 1 month;
- h. Bad habit which is difficult to withdrawal such as alcohol abuse;
- i. Poor compliance;
- j. Being pregnant, nursing or planing for pregnancy;
- k. Life expectancy less than 1 year;
- l. The investigator confirm that should not enroll in the study with any other cases.

Sample size

The sample size was calculated mainly based on the all-cause mortality results of DIFE study by retrospective cohort study, which showed that the 3 years mortality of the optimal start group was 8.38% and that of the late start group was 19.4%. The difference between the two groups was optimistic. However, hemodialysis centers of the DIFE study are all the best hemodialysis centers in China and the mortality of hemodialysis patients in these centers are lower than the national average level. According to the Chinese National Renal Data System (CNRDS) report in 2016, the 3 years mortality of patients after hemodialysis was 30.6%, and based on the experience of the IDEAL study²³. We assumed 3 years mortality in the optimal start group and late start group to be 10% and 20%. Therefore, we estimated a sample size of 198 per group (assuming I error rate (α) of 0.05, a type II error rate (β) of 0.2, two-sided test,

1
2
3 with $P < 0.05$ considered statistically significant). Assuming that 20% of participants
4 would withdraw or drop out, the target sample size was 496 participants, or 248
5 participants in each group will be recruited.
6
7

8 **Randomization and allocation**

9
10 Independent biostatisticians with no relationship to the data management and data
11 statistical analysis team will use the SAS 9.2 software (version 9.1.3; SAS Institute,
12 Inc., Cary, NC, USA) stratified by site to generate random numbers according to the
13 block randomization method. The investigators will allocate the random numbers to
14 eligible participants assigned 1:1 to optimal start dialysis group or late start dialysis
15 group according to the enrollment sequence. Randomization allocation and random
16 number will be sent by automated email, to the non-blind investigators performing the
17 randomization using their unique user name and password on the internet-based
18 randomization service of Randomization and Trial Supply Management system.
19
20
21
22
23
24
25
26

27 **Patient and Public Involvement**

28
29 A patient and public involvement (PPI) reference group comprising dialysis patients,
30 their partners, carers and representatives from Voluntary Sectors will be formed. The
31 PPI reference group will meet quarterly throughout the duration of the program.
32 Group members have been consulted at all stages of the work leading to this proposal,
33 provided valuable insight and advice. The trial was designed in partnership with PPI
34 to help maximizing patient benefits. Our PPI representatives have materially
35 influenced decisions on the study population, promotion and recruitment, they will
36 also continue to contribute throughout this pilot study in terms of reviewing
37 documentation for ethics approval, reading reports and contributing to dissemination
38 activities. We will also present the final results of the ADIFE trial to PPI.
39
40
41
42
43
44
45
46

47 **Treatment**

48
49 All participants receive regular treatment as usual, which include regular dietary
50 advice, anemia and Chronic Kidney Disease-Mineral and Bone Disorder management,
51 blood pressure, and volume control as recommended by the KDIGO guideline and
52 Chinese Hemodialysis Adequacy guidelines^{19, 24-27}. Different types of vascular access
53 including temporary venous catheters, arteriovenous fistula, and artificial blood vessel
54
55
56
57
58
59
60

1
2
3 are permitted to be used in all participants. The use of such catheters is based only on
4 clinical requirements. Each participating center has been advised to consider early
5 access creation in each participant to avoid delay in the subsequent hemodialysis
6 treatment.
7
8
9

10 All participants undergoing hemodialysis treatment with capacity control dialysis
11 machine, bicarbonate dialysate, blood flow volume with 200 ~ 300ml/min, disposable
12 high-flux or low-flux dialyzer with membrane area 1.3 ~ 1.6m², dialysis dose is 4
13 hours per treatment with 2 or 3 times in one week; and the recommended spKt/V is
14 more than 1.2^{19, 27, 28}. However, despite the existence of dialysis management
15 guidelines in China, there is still potential for treatment variation between the
16 participating centers.
17
18
19
20
21
22

23 **Intervention**

24 Participants allocated to the ‘optimal start dialysis’ group will commence dialysis with
25 the DIFE values between 30 and 35. Participants allocated to the “late start dialysis”
26 group were monitored based on the changes in DIFE values in the pre-dialysis visiting
27 stage every 12 weeks until their DIFE values were less than 30, and then commenced
28 dialysis. Participants allocated to the “late start dialysis” group are able to commence
29 dialysis earlier based on the recommendation of their caring physician although the
30 DIFE no less than 30, for instance, Participants appearing obvious uremia symptoms,
31 volume overload, hyperkalemia and so on, which the reasons for the early initiation of
32 dialysis to be recorded, this will allow for a subsequent analysis of actual DIFE at the
33 dialysis start time.
34
35
36
37
38
39
40
41
42

43 **Outcome measurement**

44 All enrolled participants will be followed up until death or until 144 weeks after the
45 last patient is randomized. Participants with “late start dialysis” group were assessed
46 every 12 weeks in the pre-dialysis visiting stage. During the period of post-dialysis
47 visiting stage, data will be collected every 12 weeks in the first year of follow-up and
48 every 24 weeks in the next two years of follow-up, The detailed follow-up items in
49 different visiting stage showed in table 1.
50
51
52
53
54
55

56 Comprehensive demographic data (age, gender, ethnicity, height, weight,
57

1
2
3 education, employment, etiology of ESRD, medical history, presence of comorbid
4 conditions, collected on all participants at baseline. Virology examination (Hepatitis B
5 virus antigen, hepatitis C virus antibody, human immunodeficiency virus
6 antibody, syphilis antibody), urine human chorionic gonadotropin (HCG) were tested
7 in screening stage, vital signs, which include temperature (T), heart rate (HR),
8 respiratory rate (RR), non-invasive blood pressure (BP) were monitored each
9 follow-up. Biochemical indexes including blood cell count (Red Blood Cells, White
10 Blood Cells, Platelets), hemoglobin (Hb), blood urea nitrogen (BUN),
11 serum creatinine (Scr), eGFR, electrolytes (serum sodium, serum potassium, serum
12 chloride, serum calcium, serum phosphate), alanine transaminase (ALT),
13 glutamic-oxalacetic transaminase (AST), total bilirubin (T-BIL), blood glucose,
14 serum lipid, serum ferritin (SF), parathyroid hormone (PTH), and ferritin were tested
15 every 12-24 weeks in each participating center. Inflammatory biomarkers including
16 high-sensitivity C-reactive protein (hs-CRP), IL-6, IL-10, tumor necrosis factor- α
17 (TNF- α) and β_2 -microglobulin (β_2 -MG) will be collected and tested every 24 weeks
18 by central lab in the Kidney Disease Research Institute of Dalian Medical University.
19 Nutritional status was assessed using Subjective Global Assessment (SGA)²⁹ and
20 serum albumin level every 24 weeks. Quality of life will be measured using the
21 well-validated Kidney Disease Quality of Life Short FormTM (KDQOL-SFTM)^{30, 31}
22 every 48 weeks; and cognitive function will be assessed using the Montreal Cognitive
23 Assessment (MoCA)³² every 24 weeks. Concomitant medications including calcium
24 channel blockers (CCB), statins, angiotensin-converting enzyme inhibitors (ACEI),
25 angiotensin receptor blockers (ARB), and erythropoiesis stimulating agents (ESAs)
26 are also being collected at baseline and follow-up period. Medical costs will be
27 recorded in pre-dialysis visiting stage and post-dialysis visiting stage by both the
28 questionnaire and medical insurance records of the participants, including dialysis
29 related costs, hospitalization related costs, and outpatient costs of comorbidities
30 treatment.

31
32 The all following data will be recorded on standardized online electronic case
33 report forms (eCRFs) based on electronic data acquisition system. All adverse events

(AE) will be recorded on the eCRFs on specific pages reserved for this purpose. Serious adverse events (SAE) are defined as death, life-threatening, hospitalization (or prolongation of initial hospitalization), cause disability or cause permanent damage, a congenital anomaly, or birth defect. Completed eCRFs entered into a secured central database for independent quality control and centralized analysis.

Table 1 The Follow-up items in different visiting stage of ADIFE study

Follow-up items	Screening stage	Pre-dialysis visiting stage	Post-dialysis visiting stage
			V0~V8 (0~144w)
Signed informed consent form	√	-	-
Inclusion and exclusion criteria	√	-	-
Demographic data	√	-	-
Vital signs, physical examination	√	√	√ (V0~V8)
Urine HCG	√	-	-
Virology examination	√	-	-
Blood routine test	√	√	√ (V0~V8)
BUN, Scr, eGFR, Alb, Electrolytes,	√	√	√ (V0~V8)
ALT, AST, T-BIL, Blood glucose, Serum lipid, serum Ferrium	-	-	√ (V0, V4, V6, V8)
PTH, Ferritin	-	-	√ (V0, V2, V4~V8)
Hs-CRP, IL-6, IL-10, TNF- α , β_2 -MG	-	-	√ (V0, V2, V4~V8)
KDQoL-SF	-	-	√ (V0, V4, V6, V8)
MoCA	-	-	√ (V0, V2, V4~V8)
SGA	-	-	√ (V0, V2, V4~V8)
Vascular access	-	-	√ (V0~V8)
Medical costs	-	√	√ (V0~V8)
Complications related to dialysis	-	-	√ (V0~V8)
AE, SAE	-	√	√ (V0~V8)
Concomitant medications	-	√	√ (V0~V8)

Note: “√” represent selected follow-up items; “-” represent not-selected follow-up items. HCG, human chorionic gonadotropin; BUN, blood urea nitrogen; Scr, serum creatinine; eGFR, estimate glomerular filtration rate; ALB, albumin; ALT, alanine transaminase; AST, glutamic-oxalacetic transaminase; T-BIL, total bilirubin; PTH, parathyroid hormone; hs-CRP,

1
2
3 high sensitive C-reactive protein; TNF- α , tumor necrosis factor- α ; β_2 -MG, β_2 -microglobulin;
4 KDQOL-SF, Kidney Disease Quality of Life Short Form; MoCA, Montreal Cognitive
5 Assessment; SGA, subjective global assessment; AE, adverse events; SAE, serious adverse
6 events.
7
8
9

10 **Endpoint measurements**

11 The primary endpoints is all-cause mortality within 3 years following randomization
12 to “optimal start dialysis” or “late start dialysis” groups. Secondary endpoints include
13 cerebro-cardiovascular events (nonfatal myocardial infarction, nonfatal stroke,
14 transient ischemic attack, new-onset angina, acute heart failure or severe arrhythmia
15 which should to be hospitalized), infectious complications, hemodialysis
16 complications (including changes of vascular access, vascular access related infection,
17 fluid and electrolyte disorders, and cognitive dysfunction), annual hospitalization
18 (proportion of participants admitted to hospital every year), quality of life, nutrition
19 assessment, cognitive dysfunction and medical costs.
20
21
22
23
24
25
26
27
28

29 **Statistical analysis**

30 For all baseline and outcome variables, the number of available measurements and the
31 number of missing values will be given. All analyses will be conducted according to
32 the intention-to-treat principle, as recommended in the Consolidated Standards of
33 Reporting Trials (CONSORT) statement. That is, all randomised patients will be
34 analysed in the groups to which they were originally allocated. Qualitative variables
35 will be described as number and percentage, and quantitative variables as number,
36 mean, and standard deviation. Quantitative variables with skewed distributions will be
37 presented as median and interquartile range (25th percentile to 75th percentile).
38
39
40
41
42
43
44

45 The characteristics of the two groups will be compared using the usual univariate tests
46 (chi-squared or Fisher’s exact test for categorical variables, and Student’s unpaired
47 t-test or the Wilcoxon rank-sum test for quantitative variables, as appropriate). We
48 used a time-to-event analysis to compare the proportions of patients with primary and
49 secondary outcomes in the two groups. The primary outcome of the all-cause
50 mortality in 3 years will be compared between optimal start and late start groups using
51 the Cochran-Mantel-Haenszel procedure, adjusting for center. In sensitivity analyses
52
53
54
55
56
57
58
59
60

1
2
3 of all-cause mortality, univariate and multivariate COX proportional hazard models
4 with inverse probability weighting (IPW) will be performed to adjust for age, diabetes,
5 cardiovascular diseases, cause of ESRD. All analyses will be performed using SAS
6 Version 9.2 (SAS Institute Inc, Cary, NC, USA) by the team of statisticians at the
7 Fuwai Hospital, China. All reported *P* values are two-sided and *P* values less than
8 0.05 will be considered to be significant.
9
10
11
12
13

14 **Ethics and dissemination**

15 **Ethics**

16
17 Ethical approval was obtained from the ethics committees of the First Affiliated
18 Hospital of Dalian Medical University (Registration No:YJ-KY-2017-119), and all
19 participating centers will also obtain additional ethics approval in accordance with
20 local practice.
21
22
23
24

25 **Informed consent and withdrawal from the study**

26
27 Each participant or authorised surrogates will sign an informed consent form. The
28 process of informed consent will be in accordance with the Declaration of Helsinki.
29 Participants were fully informed about the ADIFE study by the investigators, and
30 were able to discuss the trial process with their nephrologists and contact the
31 investigator directly to request further information. Participants and authorised
32 surrogates will received the related materials of informed consent. Participants were
33 informed of their right to withdraw from the study either at their own request or at the
34 discretion of the investigator at any time without their care being affected in any way.
35
36
37
38
39
40
41

42 **Dissemination plan**

43
44 Survey data will be exported directly from eCRF as a text file and imported in
45 electronic form for scoring and analysis using statistics software. A detailed database
46 will track participants' progress through the trial including the scheduling of
47 assessments and reminders to complete assessments. Detailed strategies, including
48 phone or text message reminders will be used to remind participants about upcoming
49 assessments. All members of the research team and other associated personnel will
50 have access to the final trial dataset in both identified and re-identifiable forms.
51
52
53
54
55

56 Print data will be stored in locked filing cabinets accessible only to the research

1
2
3 team. Electronic data will be stored on password-protected computers or servers only
4 accessible to the research team. All paper and electronic records will be retained and
5 disposed of in accordance with the requirements of the Criteria for
6 the Quality Control of Clinical Trials from the China Food and Drug Administration
7 (CFDA) .
8
9

10
11
12 Results from the outcome measures will not be presented in a way that adversely
13 affects the confidentiality of participants. The description of participants will not
14 allow identification of individual participants, and individual results and individual
15 names will not be revealed. Final reports and publications will only consist of
16 aggregated results. At the completion of the study, participants will receive a plain
17 Chinese summary of study results. Scientific reports of the main outcomes, secondary
18 outcomes and process evaluation will be submitted to an international peer-reviewed
19 journal. Results will also be presented at national and international conferences
20 relevant to the subject fields.
21
22
23
24
25
26
27

28 **Data management**

29 All information of participants will be recorded on standardized online electronic case
30 report forms (eCRFs) which will be anonymized and saved on password-protected
31 computers. The data monitoring committee (DMC) is independent from the sponsor
32 and competing interests, will meet twice yearly to review the efficacy and safety data.
33
34
35
36
37

38 **Oversight committees**

39 A Trial Steering Committee has been set-up and will include an independent chairman,
40 28 independent members and the study's investigators.
41
42

43 **Safety monitoring**

44 AE will be closely monitored. These are events that are likely to affect to a significant
45 degree the safety or physical or mental integrity of the participants in the trial. SAE
46 must be reported to the sponsor (First Affiliated Hospital of Dalian Medical
47 University, China) and the State Food and Drug Administration promptly by fax or
48 telephone by investigators, followed by a written report within 24 hours. The sponsor
49 will be notified immediately of any case where the above definition applies during the
50 trial.
51
52
53
54
55
56
57

Discussion

The timing of dialysis initiation is a risk factor affecting the prognosis of patients with ESRD. Optimal timing of dialysis initiation remains unclear. Some studies showed early start dialysis was associated with a lower risk of mortality⁵ and others studies indicated either a survival advantage of late start dialysis^{3, 11, 12, 33} or comparable mortality risk between early and late start dialysis^{34, 35}. IDEAL study indicated that using eGFR as the primary guide for when to start dialysis likely should be abandoned in a patient with progressive advanced CKD¹⁰.

The novel DIFE integrate subjective clinical variables of uremic signs and symptoms with objective biochemical markers beyond serum creatinine and eGFR for assessing timing of dialysis initiation in ESRD patients, which provide a individualized, effective and convenient tool for dialysis initiation decision making. The results of ADIFE study will provide solid evidence for evaluating the accuracy and efficacy of DIFE and maybe provide the potential optimal timing of dialysis initiation with ESRD patients approaching the need for maintenance dialysis. Some nephrologists and non-nephrologis with less trained who may not know how to interpret laboratory values and clinical signs a formula to calculate when to start dialysis can be very helpful to deliver safe care.

The DIFE formula were established through a previous retrospective multicenter cohort study with hemodialysis patients' data, the ADIFE study will further assess the clinical accuracy and availability of DIFE for guiding the timing of hemodialysis initiation, therefore, the ADIFE study excluded the Participants waiting peritoneal dialysis and transplantation, but we have already planned to assess the availability of DIFE for guiding the timing of dialysis with peritoneal dialysis patients through other clinical study.

Author contributors

All authors meet ICMJE criteria for authorship in that they have contributed substantially to the conceptual design or the processes of data collection, analysis or interpretation, the drafts and revisions of the study protocol and manuscript, granted approval of the final version of the study protocol and acknowledged their

1
2
3 accountability with regard to the integrity and accuracy of this study protocol.

4 Research idea and study design: Hongli Lin, Xiangmei Chen, Xuefeng Sun, Ximing
5 Sun, Degang Wang, Ming Fang and Lynda Szczech.

6
7 Writing and reviewing of the protocol: Jilin chen, Ying Liu, Hongli Lin and Yang
8 Wang.

9
10 Drafting of the manuscript: Jilin chen, Ying Liu and Zach Odeh will be responsible
11 for administrative and managerial procedures related to all phases of the trial, which
12 will be supervised by Hongli Lin.

13
14 Statistical analysis: Yang Wang, and Wei Li.

15
16 Participants enrollment and follow up related work: Jilin chen, Ying Liu, Hongli Lin,
17 Hongli Jiang, Wei Shi, Wenhui Liu, Ping Fu, Xiaoqiang Ding, Ming Chang, Shuxin
18 Liu, Xiao Yang, Ning Cao, Menghua Chen, Zhaohui Ni, Jing Chen, Shiren Sun,
19 Xinling Liang, Huimin Wang, Yani He, Bihu Gao, Jianqin Wang, Lirong Hao, Jian
20 Liu, Suhua Li, Qiang He, Hongmei Liu, Na Yi, Fengmin Shao, Jundong Jiao, Yuhuan
21 Ma, Li Yao, Yi Sun and Detian Li.

22 23 24 25 26 27 28 29 30 **Trial status**

31 Recruitment will commence using digital social media networks and print-based
32 advertising nationwide in April 2018. Completion of recruitment is expected in
33 December 2018. The study will be completed in December 2021.

34 35 36 37 **Acknowledgements**

38 The authors thank all staff for their support with this study and the members of the
39 patient and public involvement group for their invaluable advice. We acknowledge Dr.
40 Mark Roger Marshall (Associate Professor of University of Auckland, New Zealand)
41 for his expert guidance and helpful comments on the study design.

42 43 44 45 46 47 **Funding**

48 The ADIFE study is an investigator initiated and conducted study, This work was
49 supported by the special fund for National Health and Family Planning Commission
50 (NHFPC) Scientific Research in the Public Welfare. Grant number is 201502023.

51 The NHFPC had no role in the design, conduct, management, analysis, or
52 interpretation of the study.

1
2
3 **Conflicts of interests** None declared.
4

5 **References**

- 6 1 Woo KT, Choong HL, Wong KS, Tan HB, Chan CM. The contribution of chronic kidney disease to
7 the global burden of major noncommunicable diseases. *Kidney international*. 2012; **81**: 1044-5.
8 2 Feng L, Jin AZ, Allen JC, Chow KY, Jafar TH. Timing of commencement of maintenance dialysis and
9 mortality in young and older adults in Singapore. *BMC nephrology*. 2017; **18**: 176.
10 3 Park JY, Yoo KD, Kim YC, Kim DK, Joo KW, Kang SW, *et al*. Early dialysis initiation does not improve
11 clinical outcomes in elderly end-stage renal disease patients: A multicenter prospective cohort study.
12 *PloS one*. 2017; **12**: e0175830.
13 4 Mehrotra R, Rivara M, Himmelfarb J. Initiation of dialysis should be timely: neither early nor late.
14 *Seminars in dialysis*. 2013; **26**: 644-9.
15 5 Churchill DN. An evidence-based approach to earlier initiation of dialysis. *American journal of*
16 *kidney diseases : the official journal of the National Kidney Foundation*. 1997; **30**: 899-906.
17 6 Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong
18 survival in patients with end-stage renal failure. *Journal of the American Society of Nephrology : JASN*.
19 2002; **13**: 2125-32.
20 7 Faust J, Schreiner O. Early versus late initiation of dialysis. *The New England journal of medicine*.
21 2010; **363**: 2368-9; author reply 69-70.
22 8 Wingard RL, Pupim LB, Krishnan M, Shintani A, Ikizler TA, Hakim RM. Early intervention improves
23 mortality and hospitalization rates in incident hemodialysis patients: RightStart program. *Clinical*
24 *journal of the American Society of Nephrology : CJASN*. 2007; **2**: 1170-5.
25 9 Korevaar JC, Jansen MA, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, *et al*. When to initiate
26 dialysis: effect of proposed US guidelines on survival. *Lancet*. 2001; **358**: 1046-50.
27 10 Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, *et al*. A randomized, controlled
28 trial of early versus late initiation of dialysis. *The New England journal of medicine*. 2010; **363**: 609-19.
29 11 Wright S, Klausner D, Baird B, Williams ME, Steinman T, Tang H, *et al*. Timing of dialysis initiation
30 and survival in ESRD. *Clinical journal of the American Society of Nephrology : CJASN*. 2010; **5**: 1828-35.
31 12 Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC, Taiwan Society of N. Impact of the clinical
32 conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study
33 in Taiwan. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and*
34 *Transplant Association - European Renal Association*. 2010; **25**: 2616-24.
35 13 Susantitaphong P, Altamimi S, Ashkar M, Balk EM, Stel VS, Wright S, *et al*. GFR at initiation of
36 dialysis and mortality in CKD: a meta-analysis. *American journal of kidney diseases : the official journal*
37 *of the National Kidney Foundation*. 2012; **59**: 829-40.
38 14 Zaman T, Filipowicz R, Beddhu S. Implications and importance of skeletal muscle mass in
39 estimating glomerular filtration rate at dialysis initiation. *Journal of renal nutrition : the official journal*
40 *of the Council on Renal Nutrition of the National Kidney Foundation*. 2013; **23**: 233-6.
41 15 Escoli R, Luz I, Santos P, Vila Lobos A. Glomerular Filtration Rate and Initiation of Dialysis.
42 *Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for*
43 *Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2017; **21**:
44 606-10.
45 16 Lin X, Zeng XZ, Ai J. The Glomerular Filtration Rate (GFR) at Dialysis Initiation and Mortality in
46 Chronic Kidney Disease (CKD) in East Asian Populations: A Meta-analysis. *Internal medicine*. 2016; **55**:
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3097-104.

17 Lassalle M, Labeeuw M, Frimat L, Villar E, Joyeux V, Couchoud C, *et al.* Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. *Kidney international*. 2010; **77**: 700-7.

18 Wang AY, Woo J. Early versus late initiation of dialysis and nutrition: does a transition mean a change in dietary protein intake? *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation*. 2013; **23**: 228-32.

19 National Kidney F. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2015; **66**: 884-930.

20 Grootendorst DC, Michels WM, Richardson JD, Jager KJ, Boeschoten EW, Dekker FW, *et al.* The MDRD formula does not reflect GFR in ESRD patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2011; **26**: 1932-7.

21 Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle AJK, *et al.* SPIRIT 2013 Statement: defining standard protocol items for clinical trials. *Revista panamericana de salud publica = Pan American journal of public health*. 2015; **38**: 506-14.

22 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, *et al.* A new equation to estimate glomerular filtration rate. *Annals of internal medicine*. 2009; **150**: 604-12.

23 Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Dempster J, *et al.* The Initiating Dialysis Early and Late (IDEAL) study: study rationale and design. *Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis*. 2004; **24**: 176-81.

24 Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, *et al.* KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2013; **62**: 201-13.

25 Klinger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, *et al.* KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2013; **62**: 849-59.

26 Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, *et al.* KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2017; **70**: 737-51.

27 Group CNAHAC. Clinical practice guide for Chinese hemodialysis adequacy. *Natl Med J China*. 2015; **95**: 2748-53.

28 Chen XM, Ding XQ, Liu FY, Liu ZH, Chen JH. Blood Purification Standard Operating Procedure(SOP):2010 version. 2010.

29 Raguso CA, Maisonneuve N, Pichard C. [Subjective Global Assessment (SGA): evaluation and followup of nutritional state]. *Revue medicale de la Suisse romande*. 2004; **124**: 607-10.

30 Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. *Qual Life Res*. 1994; **3**: 329-38.

31 Hays RD KJ, Mapes D, Coons S, Amin N, Carter WB, Kamberg C. Kidney Disease Quality of Life Short Form (KDQOL-SF™), Version 1.3: A Manual for Use and Scoring.

32 Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, *et al.* The Montreal

1
2
3 Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the*
4 *American Geriatrics Society*. 2005; **53**: 695-9.

5 33 Pan Y, Xu XD, Guo LL, Cai LL, Jin HM. Association of early versus late initiation of dialysis with
6 mortality: systematic review and meta-analysis. *Nephron Clinical practice*. 2012; **120**: c121-31.


7
8 34 Yamagata K, Nakai S, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese
9 Society for Dialysis T. Late dialysis start did not affect long-term outcome in Japanese dialysis patients:
10 long-term prognosis from Japanese Society for [corrected] Dialysis Therapy Registry. *Therapeutic*
11 *apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the*
12 *Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2012; **16**: 111-20.

13
14 35 Scialla JJ, Liu J, Crews DC, Guo H, Bandeen-Roche K, Ephraim PL, *et al*. An instrumental variable
15 approach finds no associated harm or benefit with early dialysis initiation in the United States. *Kidney*
16 *international*. 2014; **86**: 798-809.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1 **Trial Flow Diagram of the ADIFE study**. The whole trial flow including the screening stage within seven days, pre-dialysis visiting stage and post-dialysis visiting stage of visit 0 ~ visit 8. Enrolled subjects will be randomised 1:1 to the optimal start dialysis group with DIFE value between 30 and 35 or late start dialysis group with DIFE value less than 30. Participants will be followed up at baseline (visit 0) , pre-dialysis visiting stage every 12 weeks, and post-dialysis visiting stage every 12 or 24 weeks. ESRD, End-Stage Renal Disease; DIFE, Dialysis Initiation based on Fuzzy-mathematics Equation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Trial Flow Diagram of the ADIFE study

90x40mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	17
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1-3,16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	15

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	17
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	15
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5-7
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	5-7
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	6-7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	7-8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	9-10
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	9-12
8	adherence		and any procedures for monitoring adherence (eg, drug	
9			tablet return; laboratory tests)	
10				
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	9-10
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	10-13
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	Figure 1
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	8
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	14
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	9
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence until interventions are assigned	
2				
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9
5	implementation			
6				
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
10				
11				
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
15	emergency			
16	unblinding			
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	15
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
32	retention			
33				
34				
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	15
39				
40				
41				
42				
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
47				
48				
49				
50				
51	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13
52	analyses			
53				
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13
56	population and			
57	missing data			
58				
59				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	15
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	15
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	15
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	14
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	14
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	14-15
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	17
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	15
60				

1		and disclosure of contractual agreements that limit such	
2		access for investigators	
3			
4	Ancillary and post	#30 Provisions, if any, for ancillary and post-trial care, and for	n/a
5	trial care	compensation to those who suffer harm from trial	
6		participation	
7			
8			
9	Dissemination policy:	#31a Plans for investigators and sponsor to communicate trial	15
10	trial results	results to participants, healthcare professionals, the public,	
11		and other relevant groups (eg, via publication, reporting in	
12		results databases, or other data sharing arrangements),	
13		including any publication restrictions	
14			
15			
16			
17	Dissemination policy:	#31b Authorship eligibility guidelines and any intended use of	n/a
18	authorship	professional writers	
19			
20			
21	Dissemination policy:	#31c Plans, if any, for granting public access to the full protocol,	n/a
22	reproducible	participant-level dataset, and statistical code	
23	research		
24			
25			
26			
27	Informed consent	#32 Model consent form and other related documentation given	14
28	materials	to participants and authorised surrogates	
29			
30			
31	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of	n/a
32		biological specimens for genetic or molecular analysis in the	
33		current trial and for future use in ancillary studies, if	
34		applicable	
35			
36			

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 38 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 39 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): a study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023162.R2
Article Type:	Protocol
Date Submitted by the Author:	22-Feb-2019
Complete List of Authors:	<p>Chen, Jilin; Graduate School of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University, Nephrology, Liu, Ying; Graduate School of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University Chen, Xiangmei; Chinese PLA General Hospital, Nephrology Sun, Xuefeng; Chinese PLA General Hospital, Nephrology Li, Wei; Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Yang, Wang; Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Li, Ping; Military General Hospital of Beijing PLA Sun, Ximing; Dalian University of Technology Wang, Degang; Dalian University of Technology Jiang, Hongli; The First Affiliated Hospital of Xi'an Jiaotong University Shi, Wei; Guangdong General Hospital, Guangdong Academy of Medical Sciences, Liu, Wenhui; Beijing Friendship Hospital Attached Capital Medical University, Department of Nephrology Fu, Ping; West China Hospital of Sichuan University Ding, X. Q.; Zhongshan Hospital, Fudan University, Chang, Ming; Dalian Municipal Central Hospital Liu, Shuxin; Dalian Municipal Central Hospital Yang, Xiao; The First Affiliated Hospital, Sun Yat-sen University Cao, Ning; General Hospital of Shenyang Military Region Chen, Menghua; General Hospital of Ningxia Medical University Ni, Zhao-Hui; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chen, Jing; Huashan Hospital, Fudan University Sun, Shiren; The Fourth Military Medical University Liang, Xinling; Guangdong General Hospital Wang, Huimin; General Hospital of Benxi Iron and Steel Co., Ltd. He, Yani; Daping Hospital Affiliated to Army Military Medical University Gao, Bihu; Affiliated Zhong Shan Hospital of Dalian University, Wang, Jianqin; Lanzhou University Second Hospital Hao, Lirong; the First Affiliated Hospital of Harbin Medical University, Liu, Jian; The First Affiliated Hospital of Xinjiang Medical University Li, Suhua; The First Affiliated Hospital of Xinjiang Medical University He, Qiang; Zhejiang Provincial People's Hospital Liu, Hongmei; An Steel Group Hospital</p>

	<p>Yi, Na; An Steel Group Hospital Shao, Fengmin; The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital Jiao, Jundong; The Second Affiliated Hospital of Harbin Medical University Ma, Yuhuan; General Hospital of Mining Industry Group FuXin Yao, Li; The First Hospital of China Medical University Sun, Yi; General Hospital Affiliated To Shenyang Medical College Li, Detian; Shengjing Hospital of China Medical University Szczech, Lynda; FibroGen, Inc Fang, Ming; the First Affiliated Hospital of Dalian Medical University Odeh, Zach; Dalian Medical University Graduate School Lin, Hongli; The First Affiliated Hospital of Dalian Medical University , Kidney Disease Research Institute, Department of nephrology</p>
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	End-Stage Renal Disease, Hemodialysis, Timing of Dialysis Initiation, Fuzzy mathematics

SCHOLARONE™
 Manuscripts

1
2
3
4 **Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): a**
5 **study protocol for a randomised controlled trial**
6
7

8
9 Jilin Chen, MD^{1,2,&}, Ying Liu, MD^{1,2,&}, Xiangmei Chen, MD, PhD³, Xuefeng Sun, MD,
10 PhD³, Wei Li, PhD⁴, Yang Wang, MPH⁴, Ping Li, PhD³, Ximing Sun⁵, Degang Wang⁵,
11 Hongli Jiang, MD⁶, Wei Shi, MD, PhD⁷, Wenhui Liu, MD, PhD⁸, Ping Fu, MD, PhD⁹,
12 Xiaoqiang Ding, MD, PhD¹⁰, Ming Chang, MM¹¹, Shuxin Liu, PhD¹¹, Xiao Yang, MD,
13 PhD¹², Ning Cao, PhD¹³, Menghua Chen, PhD¹⁴, Zhaohui Ni, MD, PhD¹⁵, Jing Chen,
14 MD, PhD¹⁶, Shiren Sun, MD, PhD¹⁷, Xinling Liang, MD, PhD⁷, Huimin Wang, MM¹⁸,
15 Yani He, MD, PhD¹⁹, Bihu Gao, PhD²⁰, Jianqin Wang, PhD²¹, Lirong Hao, MD, PhD²²,
16 Jian Liu, MD, PhD²³, Suhua Li, MD²³, Qiang He, PhD²⁴, Hongmei Liu, MM²⁵, Na Yi,
17 MM²⁵, Fengmin Shao, PhD²⁶, Jundong Jiao, MD, PhD²⁷, Yuhuan Ma, MM²⁸, Li Yao,
18 MD, PhD²⁹, Yi Sun, MD, PhD³⁰, Detian Li, MD, PhD³¹, Lynda Szczech, MD, MSCE³²,
19 Ming Fang, MD², Zach Odeh, MS¹, Hongli Lin, MD, PhD^{2,*}
20
21
22
23
24
25
26
27
28
29

30
31 ¹ Graduate School of Dalian Medical University, Dalian, China

32
33 ² Kidney Disease Research Institute, Department of Nephrology, the First Affiliated
34 Hospital of Dalian Medical University, Dalian, China

35
36
37 ³ Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of
38 Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research
39 Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research,
40 Beijing, China

41
42
43
44 ⁴ Medical Research & Biometrics Center, Fuwai Hospital, National Center for
45 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union
46 Medical College, Beijing, China

47
48
49
50 ⁵ School of Control Science and Engineering, Dalian University of Technology, Dalian,
51 China

52
53
54 ⁶ Blood Purification Center, The First Affiliated Hospital of Xi'an Jiaotong University,
55 Xi'an, China

56
57
58 ⁷ Division of Nephrology, Guangdong General Hospital, Guangdong Academy of
59 Medical Sciences, Guangzhou, China.
60

1
2
3
4 ⁸ Division of Nephrology, Beijing Friendship Hospital, Capital Medical University,
5 Beijing, China

6
7
8 ⁹ Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan
9 University, Chengdu, China

10
11 ¹⁰ Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China

12
13 ¹¹ Division of Nephrology, Dalian Municipal Central Hospital, Dalian, China

14
15 ¹² Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University,
16 Key Laboratory of Nephrology, Ministry of Health of China, Guangzhou, China

17
18 ¹³ Blood Purification Center, General Hospital of Shenyang Military Region, Shenyang,
19 China

20
21 ¹⁴ Department of Nephrology, General Hospital of Ningxia Medical University,
22 Yinchuan, China

23
24 ¹⁵ Department of Nephrology, Renji Hospital Affiliated to Shanghai Jiaotong
25 University Medical School, Shanghai, China

26
27 ¹⁶ Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China

28
29 ¹⁷ Department of Nephrology, Xijing Hospital, The Fourth Military Medical University,
30 Xi'an, China

31
32 ¹⁸ Division of Nephrology, General Hospital of Benxi Iron and Steel Co., Ltd., Benxi,
33 China

34
35 ¹⁹ Blood Purification Center, Daping Hospital Affiliated to Army Military Medical
36 University, Chongqing, China

37
38 ²⁰ Division of Nephrology, Affiliated Zhong Shan Hospital of Dalian University,
39 Dalian, China

40
41 ²¹ Division of Nephrology, Lanzhou University Second Hospital, Lanzhou, China

42
43 ²² Division of Nephrology, the First Affiliated Hospital of Harbin Medical University,
44 Harbin, China

45
46 ²³ Division of Nephrology, The First Affiliated Hospital of Xinjiang Medical University,
47 Urumchi, China

48
49 ²⁴ Division of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou, China

50
51 ²⁵ Division of Nephrology, An Steel Group Hospital, Anshan, China

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

²⁶ Blood Purification Center, The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital, Zhengzhou, China

²⁷ Division of Nephrology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

²⁸ Division of Nephrology, General Hospital of Mining Industry Group FuXin, FuXin, China

²⁹ Division of Nephrology, The First Hospital of China Medical University, Shenyang, China

³⁰ Division of Nephrology, General Hospital Affiliated To Shenyang Medical College, Shenyang, China

³¹ Division of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.

³² FibroGen, Inc., San Francisco, CA, USA.

&These authors contributed equally to this work and should be considered as co-first authors

*Corresponding Author: Hongli Lin, Kidney Disease Research Institute, Department of nephrology, the First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Dalian 116011, China. Telephone: +86041183636963-3537. E-mail: hllin@dlmedu.edu.cn

The word count of the article: 6527 words

Abstract

Introduction Starting dialysis early or late both results in a low quality of life and a poor prognosis in hemodialysis patients. However, there remains no consensus on the optimal timing of dialysis initiation and this is mainly due to lack of suitable methods to assess variations in dialysis initiation time. We have established a novel equation named DIFE (Dialysis Initiation based on Fuzzy-mathematics Equation) through a retrospective multicenter clinical cohort study in China to find the most suitable timing of dialysis initiation. The predictors of the DIFE include nine biochemical markers and clinical variables altogether influence dialysis initiation. To verify the external validity and clinical accuracy of DIFE, we designed the ADIFE (assessment of DIFE) study by

1
2
3
4 a prospective, open-label, multicenter, randomized controlled trial to assess the clinical
5 outcomes among patients who initiate dialysis in an optimal start dialysis group and a
6 late start dialysis group based on DIFE.
7

8
9 **Methods and analysis** A total of 388 enrolled end-stage renal disease (ESRD)
10 subjects will be randomised 1:1 to the optimal start group with DIFE value between
11 30 and 35 or late start dialysis group with DIFE value less than 30 using the
12 Randomization and Trial Supply Management (RTSM) system. Participants will be
13 assessed with signs and symptoms change, dialysis mode and parameters, biochemical
14 and inflammatory markers, Subjective Global Assessment (SGA), Kidney Disease
15 Quality of Life Short Form (KDQOL-SF™), Cognitive Assessment (MoCA), Medical
16 costs, adverse events, and concomitant medication at baseline, pre-dialysis visiting
17 stage and post-dialysis visiting stage every 12 to 24 weeks. The following data were
18 recorded on standardized online electronic case report forms (eCRFs). The primary
19 endpoint is 3 years all-cause mortality. The secondary endpoints include non-fatal
20 cerebro-cardiovascular events, annual hospitalization rate, quality of life, medical
21 costs, and hemodialysis related
22 complications.
23
24
25
26
27
28
29
30
31
32
33
34
35

36
37 **Ethics and dissemination** Ethical approval was obtained from the Ethics Committee
38 of the First Affiliated Hospital of Dalian Medical University China (Registration No:
39 YJ-KY-2017-119).
40

41
42 The final results of the ADIFE trial will be presented to the study sponsor, clinical
43 researchers and patient and public involvement. Findings will be disseminated through
44 peer-reviewed journals, Clinical Practice Guideline and at scientific meetings.
45
46
47

48
49 **Trial registration number** ClinicalTrial.gov. NCT03385902; Pre-results.

50
51 **Keywords** End-Stage Renal Disease; Hemodialysis; Timing of Dialysis Initiation;
52 Fuzzy mathematics.
53

54 **Strengths and limitations of this study**

55
56 ► We established a novel and quantifiable equation, named DIFE, which contains nine
57 laboratory and clinical parameters together that influence the timing of dialysis
58 initiation by a retrospective cohort study, which we found a significant advantages of
59
60

1
2
3
4 the DIFE for assessing the timing of dialysis initiation than estimate glomerular
5 filtration rate (eGFR) alone.

6
7 ▶ This is the first prospective randomized controlled study to assess the timing for
8 initiation of dialysis based on DIFE in patients with ESRD.

9
10
11 ▶ The study will provide acceptability and feasibility data for optimal dialysis
12 initiation based on DIFE avoiding early and late start dialysis in ESRD patients.

13
14 ▶ limitations: All participants will be recruited from 28 hemodialysis centers in china
15 which may be associated with sample selection bias.

16
17 ▶ limitations: There is no uniform dialyzer across all hemodialysis centers during
18 dialysis treatment of participants.

23 **Introduction**

24
25 The growing prevalence and incidence rate of ESRD is a global challenge¹.
26 Hemodialysis is the main treatment for patients with ESRD, and its start time has a
27 significant effect on the survival patients with ESRD²⁻⁴. Late and early start for dialysis
28 can negatively affect the quality of life and survival prognosis of patients, and this sub-
29 optimal timing of dialysis results in economic burdens for families and society⁵⁻⁷.
30 Therefore, the optimal time to commence dialysis can improve a patient's quality of
31 life by relieving a patient's uremic symptoms, lowering the patient's risk of death, and
32 by reducing medical care costs⁴. However, there is still no consensus on the optimal
33 timing for ESRD patients to initiate dialysis, and it also remains uncertain what is
34 exactly optimal timing of dialysis was associated with better outcomes. Several
35 observational studies found that earlier start of dialysis were associated with improved
36 survival and better prognosis^{5, 8, 9}. However, some cohort studies and a randomized
37 controlled trial of the Initiating Dialysis Early and Late (IDEAL) study have shown that
38 patients with early initiation of dialysis were associated with a poor survival and that
39 late initiation of dialysis had a lower risk of mortality and improved survival¹⁰⁻¹³. These
40 aforementioned findings are controversial mainly due to inefficient or outdated
41 methods for assessing dialysis timing. All of the above studies used the creatinine-based
42 estimate glomerular filtration rate (eGFR), a value whose specificity is affected by
43 nutritional status and muscle mass, calculated by either the Modified Diet in Renal
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Disease equation or the Cockcroft-Gault equation^{14, 15}. Studies showed that some
5 clinical factors such as old age, volume overload, malnutrition, diabetes, and heart
6 failure strongly influenced the timing of dialysis initiation^{5, 16-18}. Therefore, Kidney
7 Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for
8 Hemodialysis Adequacy recommend that the decision to initiation maintenance dialysis
9 should be based primarily on assessment of specific complications of kidney disease,
10 including signs and symptoms of uremia, protein-energy wasting, metabolic
11 abnormalities, and volume overload, rather than based on the eGFR alone^{19, 20}. The
12 deviation from an empirical decision to an assessment of varying clinical conditions
13 inevitably leads to a lack of consensus due to the doctor's subjective judgements, which
14 can lead to a sub-optimal decision of early or late initiation of dialysis.
15
16
17
18
19
20
21
22
23
24

25 Thus, the research team established a novel equation of timing of dialysis initiation
26 based on a Fuzzy mathematical method (DIFE) derived from a previous multicenter
27 retrospective cohort study with large-scale samples. The DIFE includes 9 parameters
28 of sex, age, blood urea nitrogen, serum creatinine, hemoglobin, albumin, serum
29 phosphorus, heart failure condition, and diabetes condition which effectively combines
30 subjective clinical variables with objective biochemical markers for dialysis initiation
31 decision making. The DIFE study showed that the 3 years dialysis mortality of patients
32 in the optimal start group (DIFE between 30 to 35) was 8.38% significantly lower than
33 the late start group (DIFE less than 30) of 19.4%. Moreover, ROC curve
34 analysis indicated that the area under curve (AUC) of prediction of 3 years death in
35 dialysis initiation assessed by the DIFE was significantly higher than that by eGFR
36 (0.73 versus 0.55, $P < 0.01$). Therefore, the DIFE was more accurate and effective for
37 assessing the timing of he modialysis initiation than eGFR alone. Furthermore, the
38 DIFE equation was convenient for popularization and application owing to
39 transforming the subjective clinical factors into objective parameters, especially for
40 non-nephrologist and doctors in primary hospitals. It may be the new standard in the
41 assessment of the timing of dialysis replacing eGFR. To further evaluate the predictive
42 ability and clinical accuracy of DIFE, we designed a prospective multicenter
43 randomized controlled trial from 28 hospitals located in different regions in China to
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 assess clinical outcomes of ESRD patients, placed in optimal or late start dialysis
5 cohorts on the basis of DIFE. The aims of the trial to assess the effect of the optimal
6 and late start dialysis, based on DIFE, using the 3 years mortality, hospitalization,
7 morbidity, quality of life, and medical costs of hemodialysis patients. The ADIFE study
8 will provide clinical evidence for the optimal time to start dialysis in ESRD patients
9 based on DIFE.
10
11
12
13
14

15 **Methods and analysis**

16 **Study design**

17
18
19 The ADIFE study is a prospective, multicenter, randomized controlled, open-label trial
20 in ESRD patients. which was divided into an “optimal start dialysis” group with DIFE
21 value between 30 and 35 and a “late start dialysis” group with DIFE value less than 30
22 respectively. The study will be implemented in 28 dialysis centers, covering the seven
23 administrative regions in China (North China, East China, South Central, Northeast,
24 Southwest and Northwest). Each participating center has systemic follow-up for the
25 participants with chronic kidney disease and can afford predialysis care including
26 preparation of vascular access in patients approaching hemodialysis.
27
28
29
30
31
32
33
34

35 Participants will be followed up at baseline, pre-dialysis visiting stage every 12
36 weeks, and post-dialysis visiting stage every 12 or 24 weeks. The whole trial flow
37 diagram is detailed in Figure 1. The protocol of ADIFE study was designed according
38 to the SPIRIT reporting guidelines²¹.
39
40
41
42

43 **Participants**

44 **Inclusion criteria**

45 Participants will enroll the study if they meet all the following requirements

- 46 a. Adults age between 18 to 75 years old;
 - 47 b. Chronic kidney disease with an eGFR (calculated by the CKD-EPI equation²²) less
48 than 15mL/min/1.73m² and the DIFE between 30 and 35;
 - 49 c. Expected to commence maintenance hemodialysis;
 - 50 d. Agreeable to randomization.
- 51
52
53
54
55
56
57

58 **Exclusion criteria**

59 Participants will be excluded if meet the one of the following items
60

- a. Acute kidney injury (AKI) or AKI on chronic kidney diseases (CKD);
- b. With the primary disease of systemic lupus erythematosus (SLE) or systemic vasculitis;
- c. Have received or planning to receive a kidney transplantation or peritoneal dialysis;
- d. Recently diagnosed cancer that was likely to impact on survival (except for cured cancer or remission for over 5 years, after radical resection of the basal cell carcinoma or squamous carcinoma of skin or carcinoma in-situ of any part of the body);
- e. Hepatocirrhosis;
- f. Positive test of Human Immunodeficiency Virus (HIV), the hepatitis B virus antigen (HBsAg) or anti-hepatitis C virus antibody (HCV Ab);
- g. Acute infection disease within 1 month;
- h. Bad habit which is difficult to withdrawal such as alcohol abuse;
- i. Poor compliance;
- j. Being pregnant, nursing or planing for pregnancy;
- k. Life expectancy less than 1 year;
- l. The investigator confirm that should not enroll in the study with any other cases.

Sample size

The sample size estimate mainly based on the primary endpoint of the 3 years all-cause mortality. On the basis of previous DIFE study with retrospective cohort study, which showed that the 3 years mortality of the optimal start group was 8.38% and that of the late start group was 19.4%. Using the PASS Version 15 of Power and Sample Size Calculation program, Therefore, we estimated a sample size of 154 per group (assuming a type I error rate of 5% with 80% power, two-sided test, with $P < 0.05$ considered statistically significant), and assuming that 20% of participants would withdraw or drop out, the target sample size was 388 participants, or 194 participants in each group will be recruited.

Randomization and allocation

Independent biostatisticians with no relationship to the data management and data statistical analysis team will use the SAS 9.2 software (version 9.1.3; SAS Institute,

1
2
3
4 Inc., Cary, NC, USA) stratified by site to generate random numbers according to the
5 block randomization method. The investigators will allocate the random numbers to
6 eligible participants assigned 1:1 to optimal start dialysis group or late start dialysis
7 group according to the enrollment sequence. Randomization allocation and random
8 number will be sent by automated email, to the non-blind investigators performing the
9 randomization using their unique user name and password on the internet-based
10 randomization service of Randomization and Trial Supply Management system.
11
12
13
14
15
16

17 **Patient and Public Involvement**

18
19 A patient and public involvement (PPI) reference group comprising dialysis patients,
20 their partners, carers and representatives from Voluntary Sectors will be formed. The
21 PPI reference group will meet quarterly throughout the duration of the program. Group
22 members have been consulted at all stages of the work leading to this proposal, provided
23 valuable insight and advice. The trial was designed in partnership with PPI to help
24 maximizing patient benefits. Our PPI representatives have materially influenced
25 decisions on the study population, promotion and recruitment, they will also continue
26 to contribute throughout this pilot study in terms of reviewing documentation for ethics
27 approval, reading reports and contributing to dissemination activities. We will also
28 present the final results of the ADIFE trial to PPI.
29
30
31
32
33
34
35
36
37

38 **Treatment**

39
40 All participants receive regular treatment as usual, which include regular dietary advice,
41 anemia and Chronic Kidney Disease-Mineral and Bone Disorder management, blood
42 pressure, and volume control as recommended by the KDIGO guideline and Chinese
43 Hemodialysis Adequacy guidelines^{19, 23-26}. Different types of vascular access including
44 temporary venous catheters, arteriovenous fistula, and artificial blood vessel are
45 permitted to be used in all participants. The use of such catheters is based only on
46 clinical requirements. Each participating center has been advised to consider early
47 access creation in each participant to avoid delay in the subsequent hemodialysis
48 treatment.
49
50
51
52
53
54
55
56

57
58 All participants undergoing hemodialysis treatment with capacity control dialysis
59 machine, bicarbonate dialysate, blood flow volume with 200 ~ 300ml/min, disposable
60

1
2
3
4 high-flux or low-flux dialyzer with membrane area 1.3 ~ 1.6m², dialysis dose is 4 hours
5 per treatment with 2 or 3 times in one week; and the recommended spKt/V is more than
6 1.2^{19, 26, 27}. However, despite the existence of dialysis management guidelines in China,
7
8 there is still potential for treatment variation between the participating centers.
9

11 **Intervention**

12
13 Participants allocated to the ‘optimal start dialysis’ group will commence dialysis with
14 the DIFE values between 30 and 35. Participants allocated to the “late start dialysis”
15 group were monitored based on the changes in DIFE values in the pre-dialysis visiting
16 stage every 12 weeks until their DIFE values were less than 30, and then commenced
17 dialysis. Participants allocated to the “late start dialysis” group are able to commence
18 dialysis earlier based on the recommendation of their caring physician although the
19 DIFE no less than 30, for instance, Participants appearing obvious uremia symptoms,
20 volume overload, hyperkalemia and so on, which the reasons for the early initiation of
21 dialysis to be recorded, this will allow for a subsequent analysis of actual DIFE at the
22 dialysis start time.
23
24

25 **Outcome measurement**

26
27 All enrolled participants will be followed up until death or until 144 weeks after the
28 last patient is randomized. Participants with “late start dialysis” group were assessed
29 every 12 weeks in the pre-dialysis visiting stage. During the period of post-dialysis
30 visiting stage, data will be collected every 12 weeks in the first year of follow-up and
31 every 24 weeks in the next two years of follow-up, The detailed follow-up items in
32 different visiting stage showed in table 1.
33

34
35 Comprehensive demographic data (age, gender, ethnicity, height, weight,
36 education, employment, causes of ESRD, medical history, presence of comorbid
37 conditions, collected on all participants at baseline. Virology examination (Hepatitis B
38 virus antigen, hepatitis C virus antibody, human immunodeficiency virus
39 antibody, syphilis antibody), urine human chorionic gonadotropin (HCG) were tested
40 in screening stage, vital signs, which include temperature (T), heart rate (HR),
41 respiratory rate (RR), non-invasive blood pressure (BP) were monitored each follow-up.
42
43 Biochemical indexes including blood cell count (Red Blood Cells, White Blood Cells,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Platelets), hemoglobin (Hb), blood urea nitrogen (BUN), serum creatinine (Scr), eGFR,
5
6 electrolytes (serum sodium, serum potassium, serum chloride, serum calcium, serum
7
8 phosphate), alanine transaminase (ALT), glutamic-oxalacetic transaminase (AST),
9
10 total bilirubin (T-BIL), blood glucose, serum lipid, serum ferritin (SF), parathyroid
11
12 hormone (PTH), and ferritin were tested every 12-24 weeks in each participating center.
13
14 Inflammatory biomarkers including high-sensitivity C-reactive protein (hs-CRP), IL-6,
15
16 IL-10, tumor necrosis factor- α (TNF- α) and β_2 -microglobulin (β_2 -MG) will be
17
18 collected and tested every 24 weeks by central lab in the Kidney Disease Research
19
20 Institute of Dalian Medical University. Nutritional status was assessed using Subjective
21
22 Global Assessment (SGA)²⁸ and serum albumin level every 24 weeks. Quality of life
23
24 will be measured using the well-validated Kidney Disease Quality of Life Short FormTM
25
26 (KDQOL-SFTM)^{29, 30} every 48 weeks; and cognitive function will be assessed using the
27
28 Montreal Cognitive Assessment (MoCA)³¹ every 24 weeks. Concomitant medications
29
30 including calcium channel blockers (CCB), statins, angiotensin-converting enzyme
31
32 inhibitors (ACEI), angiotensin receptor blockers (ARB), and erythropoiesis stimulating
33
34 agents (ESAs) are also being collected at baseline and follow-up period. Medical costs
35
36 will be recorded in pre-dialysis visiting stage and post-dialysis visiting stage by both
37
38 the questionnaire and medical insurance records of the participants, including dialysis
39
40 related costs, hospitalization related costs, and outpatient costs of comorbidities
41
42 treatment.

43
44 The all following data will be recorded on standardized online electronic case report
45
46 forms (eCRFs) based on electronic data acquisition system. All adverse events (AE)
47
48 will be recorded on the eCRFs on specific pages reserved for this purpose. Serious
49
50 adverse events (SAE) are defined as death, life-threatening, hospitalization (or
51
52 prolongation of initial hospitalization), cause disability or cause permanent damage, a
53
54 congenital anomaly, or birth defect. Completed eCRFs entered into a secured central
55
56 database for independent quality control and centralized analysis.

57
58 **Table 1 The Follow-up items in different visiting stage of ADIFE study**

Follow-up items	Screening stage	Pre-dialysis visiting stage	Post-dialysis visiting stage
			V0~V8 (0~144w)

Signed informed consent form	√	-	-
Inclusion and exclusion criteria	√	-	-
Demographic data	√	-	-
Vital signs, physical examination	√	√	√ (V0~V8)
Urine HCG	√	-	-
Virology examination	√	-	-
Blood routine test	√	√	√ (V0~V8)
BUN, Scr, eGFR, Alb, Electrolytes,	√	√	√ (V0~V8)
ALT, AST, T-BIL, Blood glucose, Serum lipid, serum Ferrium	-	-	√ (V0, V4, V6, V8)
PTH, Ferritin	-	-	√ (V0, V2, V4~V8)
Hs-CRP, IL-6, IL-10, TNF- α , β_2 -MG	-	-	√ (V0, V2, V4~V8)
KDQoL-SF	-	-	√ (V0, V4, V6, V8)
MoCA	-	-	√ (V0, V2, V4~V8)
SGA	-	-	√ (V0, V2, V4~V8)
Vascular access	-	-	√ (V0~V8)
Medical costs	-	√	√ (V0~V8)
Complications related to dialysis	-	-	√ (V0~V8)
AE, SAE	-	√	√ (V0~V8)
Concomitant medications	-	√	√ (V0~V8)

Note: “√” represent selected follow-up items; “-” represent not-selected follow-up items. HCG, human chorionic gonadotropin; BUN, blood urea nitrogen; Scr, serum creatinine; eGFR, estimate glomerular filtration rate; ALB, albumin; ALT, alanine transaminase; AST, glutamic-oxalacetic transaminase; T-BIL, total bilirubin; PTH, parathyroid hormone; hs-CRP, high sensitive C-reactive protein; TNF- α , tumor necrosis factor- α ; β_2 -MG, β_2 -microglobulin; KDQOL-SF, Kidney Disease Quality of Life Short Form; MoCA, Montreal Cognitive Assessment; SGA, subjective global assessment; AE, adverse events; SAE, serious adverse events.

Endpoint measurements

The primary endpoint is 3 years all-cause mortality following randomization to “optimal start dialysis” or “late start dialysis” groups. Secondary endpoints include

1
2
3
4 cerebro-cardiovascular events (nonfatal myocardial infarction, nonfatal stroke,
5 transient ischemic attack, new-onset angina, acute heart failure or severe arrhythmia
6 which should to be hospitalized), infectious complications, hemodialysis complications
7 (including changes of vascular access, vascular access related infection, fluid and
8 electrolyte disorders, and cognitive dysfunction), annual hospitalization (proportion of
9 participants admitted to hospital every year), quality of life, nutrition assessment ,
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cerebro-cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, transient ischemic attack, new-onset angina, acute heart failure or severe arrhythmia which should to be hospitalized), infectious complications, hemodialysis complications (including changes of vascular access, vascular access related infection, fluid and electrolyte disorders, and cognitive dysfunction), annual hospitalization (proportion of participants admitted to hospital every year), quality of life, nutrition assessment , cognitive dysfunction and medical costs.

Statistical analysis

For all baseline and outcome variables, the number of available measurements and the number of missing values will be given. All analyses will be conducted according to the intention-to-treat principle³², that is, all randomised patients will be analysed in the groups to which they were originally allocated, the noncompliance with treatment and other violations of protocol will be measured and reported as ITT effect estimate, we also will performe inverse probability weighting for adjusting selection bias due to attrition³³. Continuous variables will be checked for normal distribution and presented as the mean and SD or median and IQR as appropriate. Comparison of continuous variables will be performed by using Student t test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. Categorical variables will be presented as numbers and percentages, and analysed by the Chi-squared test. The primary outcome of the 3 years all-cause mortality will be compared between optimal start and late start groups using the Cochran-Mantel-Haenszel procedure, adjusting for center. Logistics regression model will be performed to adjust for potential confounders, such as age, sex, cause of ESRD, Comorbidity, Complication of dialysis, Dialysis mode, etc. All analyses will be performed using SAS Version 9.2 (SAS Institute Inc, Cary, NC, USA) by the team of statisticians at the Fuwai Hospital, China. All reported *P* values are two-sided and *P* values less than 0.05 will be considered to be significant.

Ethics and dissemination

Ethics

Ethical approval was obtained from the ethics committees of the First Affiliated

1
2
3
4 Hospital of Dalian Medical University (Registration No:YJ-KY-2017-119), and all
5 participating centers will also obtain additional ethics approval in accordance with local
6 practice.
7
8

9 **Informed consent and withdrawal from the study**

10
11 Each participant or authorised surrogates will sign an informed consent form. The
12 process of informed consent will be in accordance with the Declaration of Helsinki.
13 Participants were fully informed about the ADIFE study by the investigators, and were
14 able to discuss the trial process with their nephrologists and contact the investigator
15 directly to request further information. Participants and authorised surrogates will
16 received the related materials of informed consent. Participants were informed of their
17 right to withdraw from the study either at their own request or at the discretion of the
18 investigator at any time without their care being affected in any way.
19
20
21
22
23
24
25
26

27 **Dissemination plan**

28
29 Survey data will be exported directly from eCRF as a text file and imported in electronic
30 form for scoring and analysis using statistics software. A detailed database will track
31 participants' progress through the trial including the scheduling of assessments and
32 reminders to complete assessments. Detailed strategies, including phone or text
33 message reminders will be used to remind participants about upcoming assessments.
34 All members of the research team and other associated personnel will have access to
35 the final trial dataset in both identified and re-identifiable forms.
36
37
38
39
40
41

42
43 Print data will be stored in locked filing cabinets accessible only to the research
44 team. Electronic data will be stored on password-protected computers or servers only
45 accessible to the research team. All paper and electronic records will be retained and
46 disposed of in accordance with the requirements of the Criteria for
47 the Quality Control of Clinical Trial from China Food and Drug Administration
48 (CFDA) .
49
50
51
52
53

54
55 Results from the outcome measures will not be presented in a way that adversely
56 affects the confidentiality of participants. The description of participants will not allow
57 identification of individual participants, and individual results and individual names
58 will not be revealed. Final reports and publications will only consist of aggregated
59
60

1
2
3
4 results. At the completion of the study, participants will receive a plain chinese
5 summary of study results. Scientific reports of the main outcomes, secondary outcomes
6 and process evaluation will be submitted to an international peer-reviewed journals.
7 Results will also be presented at national and international conferences relevant to the
8 subject fields.
9

13 **Data management**

14 All information of participants will be recorded on standardized online electric case
15 report forms (eCRFs) which will be anonymized and saved on password-protected
16 computers. The data monitoring committee (DMC) is independent from the sponsor
17 and competing interests, will meet twice yearly to review the efficacy and safety data.
18
19

23 **Oversight committees**

24 A Trial Steering Committee has been set-up and will include an independent chairman,
25 28 independent members and the study's investigators.
26
27

29 **Safety monitoring**

30 AE will be closely monitored. These are events that are likely to affect to a significant
31 degree the safety or physical or mental integrity of the participants in the trial. SAE
32 must be reported to the sponsor (First Affiliated Hospital of Dalian Medical University,
33 China) and the State Food and Drug Administration promptly by fax or telephone by
34 investigators, followed by a written report within 24 hours, The sponsor will be notified
35 immediately of any case where the above definition applies during the trial.
36
37
38
39
40
41

42 **Discussion**

43 The timing of dialysis initiation is a risk factor affecting the prognosis of patients with
44 ESRD. Optimal timing of dialysis initiation remains unclear. Some studies showed
45 early start dialysis was associated with a lower risk of mortality⁵ and others
46 studies indicated either a survival advantage of late start dialysis^{3, 11, 12, 34} or comparable
47 mortality risk between early and late start dialysis^{35, 36}. IDEAL study indicated that
48 using eGFR as the primary guide for when to start dialysis likely should be abandoned
49 in a patient with progressive advanced CKD¹⁰.
50
51
52
53
54
55
56
57

58 The novel DIFE integrate subjective clinical variables of uremic signs and
59 symptoms with objective biochemical markers beyond serum creatinine and eGFR for
60

1
2
3
4 assessing timing of dialysis initiation in ESRD patients, which provide a individualized,
5 effective and convenient tool for dialysis initiation decision making. The results of
6 ADIFE study will provide solid evidence for evaluating the accuracy and efficacy of
7 DIFE and maybe provide the potential optimal timing of dialysis initiation with ESRD
8 patients approaching the need for maintenance dialysis. Some nephrologists and non-
9 nephrologis with less trained who may not know how to interpret laboratory values and
10 clinical signs a formula to calculate when to start dialysis can be very helpful to deliver
11 safe care.
12
13
14
15
16
17
18

19 The DIFE formula were established through a previous retrospective multicenter
20 cohort study with hemodialysis patients' data, the ADIFE study will further assess the
21 clinical accuracy and availability of DIFE for guiding the timing of hemodialysis
22 initiation, therefore, the ADIFE study excluded the Participants waiting peritoneal
23 dialysis and transplantation, but we have already planned to assess the availability of
24 DIFE for guiding the timing of dialysis with peritoneal dialysis patients through other
25 clinical study.
26
27
28
29
30
31
32

33 **Author contributors**

34 All authors meet ICMJE criteria for authorship in that they have contributed
35 substantially to the conceptual design or the processes of data collection, analysis or
36 interpretation, the drafts and revisions of the study protocol and manuscript, granted
37 approval of the final version of the study protocol and acknowledged their
38 accountability with regard to the integrity and accuracy of this study protocol.
39
40
41
42
43

44 Research idea and study design: Hongli Lin, Xiangmei Chen, Xuefeng Sun, Ximing
45 Sun, Degang Wang, Ming Fang and Lynda Szczech.
46
47

48 Writing and reviewing of the protocol: Jilin chen, Ying Liu, Hongli Lin, Ping Li and
49 Yang Wang.
50
51

52 Drafting of the manuscript: Jilin chen, Ying Liu and Zach Odeh will be responsible for
53 administrative and managerial procedures related to all phases of the trial, which will
54 be supervised by Hongli Lin.
55
56
57

58 Statistical analysis: Yang Wang, and Wei Li.
59

60 Participants enrollment and follow up related work: Jilin chen, Ying Liu, Hongli Lin,

1
2
3
4 Hongli Jiang, Wei Shi, Wenhui Liu, Ping Fu, Xiaoqiang Ding, Ming Chang, Shuxin Liu,
5
6 Xiao Yang, Ning Cao, Menghua Chen, Zhaohui Ni, Jing Chen, Shiren Sun, Xinling
7
8 Liang, Huimin Wang, Yani He, Bihu Gao, Jianqin Wang, Lirong Hao, Jian Liu, Suhua
9
10 Li, Qiang He, Hongmei Liu, Na Yi, Fengmin Shao, Jundong Jiao, Yuhuan Ma, Li Yao,
11
12 Yi Sun and Detian Li.

13 **Trial status**

14
15 Recruitment will commence using digital social media networks and print-based
16
17 advertising nationwide in April 2018. Completion of recruitment is expected in
18
19 December 2018. The study will be completed in December 2021.

20 **Acknowledgements**

21
22 The authors thank all staff for their support with this study and the members of the
23
24 patient and public involvement group for their invaluable advice. We acknowledge Dr.
25
26 Mark Roger Marshall (Associate Professor of University of Auckland, New Zealand)
27
28 for his expert guidance and helpful comments on the study design.

29 **Funding**

30
31 The ADIFE study is an investigator initiated and conducted study, This work was
32
33 supported by the special fund for National Health and Family Planning Commission
34
35 (NHFPC) Scientific Research in the Public Welfare. Grant number is 201502023.

36
37 The NHFPC had no role in the design, conduct, management, analysis, or interpretation
38
39 of the study.

40
41 **Conflicts of interests** None.

42 **References**

- 43 1 Woo KT, Choong HL, Wong KS, Tan HB, Chan CM. The contribution of chronic kidney disease to
44 the global burden of major noncommunicable diseases. *Kidney international*. 2012; **81**: 1044-5.
- 45 2 Feng L, Jin AZ, Allen JC, Chow KY, Jafar TH. Timing of commencement of maintenance dialysis and
46 mortality in young and older adults in Singapore. *BMC nephrology*. 2017; **18**: 176.
- 47 3 Park JY, Yoo KD, Kim YC, Kim DK, Joo KW, Kang SW, *et al*. Early dialysis initiation does not improve
48 clinical outcomes in elderly end-stage renal disease patients: A multicenter prospective cohort study.
49 *PLoS one*. 2017; **12**: e0175830.
- 50 4 Mehrotra R, Rivara M, Himmelfarb J. Initiation of dialysis should be timely: neither early nor late.
51 *Seminars in dialysis*. 2013; **26**: 644-9.
- 52 5 Churchill DN. An evidence-based approach to earlier initiation of dialysis. *American journal of*
53 *kidney diseases : the official journal of the National Kidney Foundation*. 1997; **30**: 899-906.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 6 Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. *Journal of the American Society of Nephrology : JASN*. 2002; **13**: 2125-32.
- 7 Faust J, Schreiner O. Early versus late initiation of dialysis. *The New England journal of medicine*. 2010; **363**: 2368-9; author reply 69-70.
- 8 Wingard RL, Pupim LB, Krishnan M, Shintani A, Ikizler TA, Hakim RM. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. *Clinical journal of the American Society of Nephrology : CJASN*. 2007; **2**: 1170-5.
- 9 Korevaar JC, Jansen MA, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, *et al*. When to initiate dialysis: effect of proposed US guidelines on survival. *Lancet*. 2001; **358**: 1046-50.
- 10 Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, *et al*. A randomized, controlled trial of early versus late initiation of dialysis. *The New England journal of medicine*. 2010; **363**: 609-19.
- 11 Wright S, Klausner D, Baird B, Williams ME, Steinman T, Tang H, *et al*. Timing of dialysis initiation and survival in ESRD. *Clinical journal of the American Society of Nephrology : CJASN*. 2010; **5**: 1828-35.
- 12 Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC, Taiwan Society of N. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2010; **25**: 2616-24.
- 13 Susantitaphong P, Altamimi S, Ashkar M, Balk EM, Stel VS, Wright S, *et al*. GFR at initiation of dialysis and mortality in CKD: a meta-analysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2012; **59**: 829-40.
- 14 Zaman T, Filipowicz R, Beddhu S. Implications and importance of skeletal muscle mass in estimating glomerular filtration rate at dialysis initiation. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation*. 2013; **23**: 233-6.
- 15 Escoli R, Luz I, Santos P, Vila Lobos A. Glomerular Filtration Rate and Initiation of Dialysis. *Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2017; **21**: 606-10.
- 16 Lin X, Zeng XZ, Ai J. The Glomerular Filtration Rate (GFR) at Dialysis Initiation and Mortality in Chronic Kidney Disease (CKD) in East Asian Populations: A Meta-analysis. *Internal medicine*. 2016; **55**: 3097-104.
- 17 Lassalle M, Labeeuw M, Frimat L, Villar E, Joyeux V, Couchoud C, *et al*. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. *Kidney international*. 2010; **77**: 700-7.
- 18 Brown MA, Collett GK, Josland EA, Foote C, Li Q, Brennan FP. CKD in elderly patients managed without dialysis: survival, symptoms, and quality of life. *Clinical journal of the American Society of Nephrology : CJASN*. 2015; **10**: 260-8.
- 19 National Kidney F. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2015; **66**: 884-930.
- 20 Grootendorst DC, Michels WM, Richardson JD, Jager KJ, Boeschoten EW, Dekker FW, *et al*. The MDRD formula does not reflect GFR in ESRD patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2011; **26**: 1932-7.

- 1
2
3
4 21 Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle AJK, *et al*. SPIRIT 2013 Statement:
5 defining standard protocol items for clinical trials. *Revista panamericana de salud publica = Pan*
6 *American journal of public health*. 2015; **38**: 506-14.
- 7
8 22 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, *et al*. A new equation to
9 estimate glomerular filtration rate. *Annals of internal medicine*. 2009; **150**: 604-12.
- 10
11 23 Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, *et al*. KDOQI US commentary on
12 the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. *American journal*
13 *of kidney diseases : the official journal of the National Kidney Foundation*. 2013; **62**: 201-13.
- 14
15 24 Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, *et al*. KDOQI US commentary
16 on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *American journal of kidney diseases :*
17 *the official journal of the National Kidney Foundation*. 2013; **62**: 849-59.
- 18
19 25 Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, *et al*. KDOQI US
20 Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation,
21 Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *American*
22 *journal of kidney diseases : the official journal of the National Kidney Foundation*. 2017; **70**: 737-51.
- 23
24 26 Group CNAHAC. Clinical practice guide for Chinese hemodialysis adequacy. *Natl Med J China*. 2015;
25 **95**: 2748-53.
- 26
27 27 Chen XM, Ding XQ, Liu FY, Liu ZH, Chen JH. Blood Purification Standard Operating
28 Procedure(SOP):2010 version. 2010.
- 29
30 28 Raguso CA, Maisonneuve N, Pichard C. [Subjective Global Assessment (SGA): evaluation and
31 followup of nutritional state]. *Revue medicale de la Suisse romande*. 2004; **124**: 607-10.
- 32
33 29 Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of
34 life (KDQOL) instrument. *Qual Life Res*. 1994; **3**: 329-38.
- 35
36 30 Hays RD KJ, Mapes D, Coons S, Amin N, Carter WB, Kamberg C. Kidney Disease Quality of Life Short
37 Form (KDQOL-SF™), Version 1.3: A Manual for Use and Scoring.
- 38
39 31 Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, *et al*. The Montreal
40 Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the*
41 *American Geriatrics Society*. 2005; **53**: 695-9.
- 42
43 32 Mansournia MA, Higgins JP, Sterne JA, Hernan MA. Biases in Randomized Trials: A Conversation
44 Between Trialists and Epidemiologists. *Epidemiology*. 2017; **28**: 54-59.
- 45
46 33 Mansournia MA, Altman DG. Inverse probability weighting. *Bmj*. 2016; **352**: i189.
- 47
48 34 Pan Y, Xu XD, Guo LL, Cai LL, Jin HM. Association of early versus late initiation of dialysis with
49 mortality: systematic review and meta-analysis. *Nephron Clinical practice*. 2012; **120**: c121-31.
- 50
51 35 Yamagata K, Nakai S, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese
52 Society for Dialysis T. Late dialysis start did not affect long-term outcome in Japanese dialysis patients:
53 long-term prognosis from Japanese Society for [corrected] Dialysis Therapy Registry. *Therapeutic*
54 *apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the*
55 *Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2012; **16**: 111-20.
- 56
57 36 Scialla JJ, Liu J, Crews DC, Guo H, Bandeen-Roche K, Ephraim PL, *et al*. An instrumental variable
58 approach finds no associated harm or benefit with early dialysis initiation in the United States. *Kidney*
59 *international*. 2014; **86**: 798-809.
- 60

Figure legends

Figure 1 **Trial Flow Diagram of the ADIFE study.** The whole trial flow including the screening stage within seven days, pre-dialysis visiting stage and post-dialysis visiting stage of visit 0 ~ visit 8. Enrolled subjects will be randomised 1:1 to the optimal start dialysis group with DIFE value between 30 and 35 or late start dialysis group with DIFE value less than 30. Participants will be followed up at baseline (visit 0) , pre-dialysis visiting stage every 12 weeks, and post-dialysis visiting stage every 12 or 24 weeks. ESRD, End-Stage Renal Disease; DIFE, Dialysis Initiation based on Fuzzy-mathematics Equation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Trial Flow Diagram of the ADIFE study

90x40mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	17
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1-3,16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	15

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	17
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	15
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5-7
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	5-7
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	6-7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	7-8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	9-10
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	9-12
8	adherence		and any procedures for monitoring adherence (eg, drug	
9			tablet return; laboratory tests)	
10				
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	9-10
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	10-13
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	Figure 1
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	8
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	14
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	9
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	9
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	n/a
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	15
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	15
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	15
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	13
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	13
53	analyses		adjusted analyses)	
54				
55				
56	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	13
57	population and		adherence (eg, as randomised analysis), and any statistical	
58	missing data		methods to handle missing data (eg, multiple imputation)	
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	15
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	15
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	15
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	14
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	14
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	14-15
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	17
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	15
60				

1		and disclosure of contractual agreements that limit such	
2		access for investigators	
3			
4	Ancillary and post	#30 Provisions, if any, for ancillary and post-trial care, and for	n/a
5	trial care	compensation to those who suffer harm from trial	
6		participation	
7			
8			
9	Dissemination policy:	#31a Plans for investigators and sponsor to communicate trial	15
10	trial results	results to participants, healthcare professionals, the public,	
11		and other relevant groups (eg, via publication, reporting in	
12		results databases, or other data sharing arrangements),	
13		including any publication restrictions	
14			
15			
16			
17	Dissemination policy:	#31b Authorship eligibility guidelines and any intended use of	n/a
18	authorship	professional writers	
19			
20			
21	Dissemination policy:	#31c Plans, if any, for granting public access to the full protocol,	n/a
22	reproducible	participant-level dataset, and statistical code	
23	research		
24			
25			
26			
27	Informed consent	#32 Model consent form and other related documentation given	14
28	materials	to participants and authorised surrogates	
29			
30			
31	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of	n/a
32		biological specimens for genetic or molecular analysis in the	
33		current trial and for future use in ancillary studies, if	
34		applicable	
35			
36			

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 38 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 39 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): A study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023162.R3
Article Type:	Protocol
Date Submitted by the Author:	08-May-2019
Complete List of Authors:	<p>Chen, Jilin; Graduate School of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University, Nephrology, Liu, Ying; Graduate School of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University Chen, Xiangmei; Chinese PLA General Hospital, Nephrology Sun, Xuefeng; Chinese PLA General Hospital, Nephrology Li, Wei; Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Yang, Wang; Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College Li, Ping; Military General Hospital of Beijing PLA Sun, Ximing; Dalian University of Technology Wang, Degang; Dalian University of Technology Jiang, Hongli; The First Affiliated Hospital of Xi'an Jiaotong University Shi, Wei; Guangdong General Hospital, Guangdong Academy of Medical Sciences, Liu, Wenhui; Beijing Friendship Hospital Attached Capital Medical University, Department of Nephrology Fu, Ping; West China Hospital of Sichuan University Ding, X. Q.; Zhongshan Hospital, Fudan University, Chang, Ming; Dalian Municipal Central Hospital Liu, Shuxin; Dalian Municipal Central Hospital Yang, Xiao; The First Affiliated Hospital, Sun Yat-sen University Cao, Ning; General Hospital of Shenyang Military Region Chen, Menghua; General Hospital of Ningxia Medical University Ni, Zhao-Hui; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chen, Jing; Huashan Hospital, Fudan University Sun, Shiren; The Fourth Military Medical University Liang, Xinling; Guangdong General Hospital Wang, Huimin; General Hospital of Benxi Iron and Steel Co., Ltd. He, Yani; Daping Hospital Affiliated to Army Military Medical University Gao, Bihu; Affiliated Zhong Shan Hospital of Dalian University, Wang, Jianqin; Lanzhou University Second Hospital Hao, Lirong; the First Affiliated Hospital of Harbin Medical University, Liu, Jian; The First Affiliated Hospital of Xinjiang Medical University Li, Suhua; The First Affiliated Hospital of Xinjiang Medical University He, Qiang; Zhejiang Provincial People's Hospital Liu, Hongmei; An Steel Group Hospital</p>

	<p>Yi, Na; An Steel Group Hospital Shao, Fengmin; The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital Jiao, Jundong; The Second Affiliated Hospital of Harbin Medical University Ma, Yuhuan; General Hospital of Mining Industry Group FuXin Yao, Li; The First Hospital of China Medical University Sun, Yi; General Hospital Affiliated To Shenyang Medical College Li, Detian; Shengjing Hospital of China Medical University Szczech, Lynda; FibroGen, Inc Fang, Ming; the First Affiliated Hospital of Dalian Medical University Odeh, Zach; Dalian Medical University Graduate School Lin, Hongli; The First Affiliated Hospital of Dalian Medical University , Kidney Disease Research Institute, Department of nephrology</p>
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	End-Stage Renal Disease, Hemodialysis, Timing of Dialysis Initiation, Fuzzy mathematics

SCHOLARONE™
 Manuscripts

1
2
3
4 **Assessment of Dialysis Initiation by a Fuzzy mathematics Equation (ADIFE): A**
5 **study protocol for a randomized controlled trial**
6

7 Jilin Chen,^{1,2,&} Ying Liu,^{1,2,&} Xiangmei Chen,³ Xuefeng Sun,³ Wei Li,⁴ Yang Wang,⁴
8 Ping Li,³ Ximing Sun,⁵ Degang Wang,⁵ Hongli Jiang,⁶ Wei Shi,⁷ Wenhui Liu,⁸ Ping
9 Fu,⁹ Xiaoqiang Ding,¹⁰ Ming Chang,¹¹ Shuxin Liu,¹¹ Xiao Yang,¹² Ning Cao,¹³
10 Menghua Chen,¹⁴ Zhaohui Ni,¹⁵ Jing Chen,¹⁶ Shiren Sun,¹⁷ Xinling Liang,⁷ Huimin
11 Wang,¹⁸ Yani He,¹⁹ Bihu Gao,²⁰ Jianqin Wang,²¹ Lirong Hao,²² Jian Liu,²³ Suhua Li,²³
12 Qiang He,²⁴ Hongmei Liu,²⁵ Na Yi,²⁵ Fengmin Shao,²⁶ Jundong Jiao,²⁷ Yuhuan Ma,²⁸
13 Li Yao,²⁹ Yi Sun,³⁰ Detian Li,³¹ Lynda Szczech,³² Ming Fang,² Zach Odeh,¹ Hongli
14 Lin,^{2,*}
15
16
17
18
19
20
21
22

23 ¹ Graduate School of Dalian Medical University, Dalian, China

24 ² Kidney Disease Research Institute, Department of Nephrology, the First Affiliated
25 Hospital of Dalian Medical University, Dalian, China

26 ³ Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute
27 of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research
28 Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research,
29 Beijing, China

30 ⁴ Medical Research & Biometrics Center, Fuwai Hospital, National Center for
31 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union
32 Medical College, Beijing, China

33 ⁵ School of Control Science and Engineering, Dalian University of Technology,
34 Dalian, China

35 ⁶ Blood Purification Center, The First Affiliated Hospital of Xi'an Jiaotong
36 University, Xi'an, China

37 ⁷ Division of Nephrology, Guangdong General Hospital, Guangdong Academy of
38 Medical Sciences, Guangzhou, China.

39 ⁸ Division of Nephrology, Beijing Friendship Hospital, Capital Medical University,
40 Beijing, China

41 ⁹ Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan
42 University, Chengdu, China
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 10 Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
5
6 11 Division of Nephrology, Dalian Municipal Central Hospital, Dalian, China
7
8 12 Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University,
9
10 Key Laboratory of Nephrology, Ministry of Health of China, Guangzhou, China
11
12 13 Blood Purification Center, General Hospital of Shenyang Military Region,
13
14 Shenyang, China
15
16 14 Department of Nephrology, General Hospital of Ningxia Medical University,
17
18 Yinchuan, China
19
20 15 Department of Nephrology, Renji Hospital Affiliated to Shanghai Jiaotong
21
22 University Medical School, Shanghai, China
23
24 16 Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China
25
26 17 Department of Nephrology, Xijing Hospital, The Fourth Military Medical
27
28 University, Xi'an, China
29
30 18 Division of Nephrology, General Hospital of Benxi Iron and Steel Co., Ltd., Benxi,
31
32 China
33
34 19 Blood Purification Center, Daping Hospital Affiliated to Army Military Medical
35
36 University, Chongqing, China
37
38 20 Division of Nephrology, Affiliated Zhong Shan Hospital of Dalian University,
39
40 Dalian, China
41
42 21 Division of Nephrology, Lanzhou University Second Hospital, Lanzhou, China
43
44 22 Division of Nephrology, the First Affiliated Hospital of Harbin Medical University,
45
46 Harbin, China
47
48 23 Division of Nephrology, The First Affiliated Hospital of Xinjiang Medical
49
50 University, Urumchi, China
51
52 24 Division of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou, China
53
54 25 Division of Nephrology, An Steel Group Hospital, Anshan, China
55
56 26 Blood Purification Center, The People's Hospital of Zhengzhou University &
57
58 Henan Provincial People's Hospital, Zhengzhou, China
59
60 27 Division of Nephrology, The Second Affiliated Hospital of Harbin Medical
University, Harbin, China

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

²⁸ Division of Nephrology, General Hospital of Mining Industry Group FuXin, FuXin, China

²⁹ Division of Nephrology, The First Hospital of China Medical University, Shenyang, China

³⁰ Division of Nephrology, Central Hospital Affiliated To Shenyang Medical College, Shenyang, China

³¹ Division of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China

³² FibroGen, Inc., San Francisco, CA, USA.

&These authors contributed equally to this work and should be considered as co-first authors

*Corresponding Author: Hongli Lin, Kidney Disease Research Institute, Department of nephrology, the First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Dalian 116011, China. Telephone: +86041183636963-3537. E-mail: hllin@dlmedu.edu.cn

The word count of the article: 6292 words

ABSTRACT

Introduction Starting dialysis early or late both result in a low quality of life and a poor prognosis in patients undergoing hemodialysis. However, there remains no consensus on the optimal timing of dialysis initiation, mainly because of a lack of suitable methods to assess variations in dialysis initiation time. We have established a novel equation named DIFE (Dialysis Initiation based on Fuzzy-mathematics Equation) through a retrospective, multicenter clinical cohort study in China to determine the most suitable timing of dialysis initiation. The predictors of the DIFE include nine biochemical markers and clinical variables that together influence dialysis initiation. To externally validate the clinical accuracy of DIFE, we designed the ADIFE (assessment of DIFE) study as a prospective, open-label, multicenter, randomized controlled trial to assess the clinical outcomes among patients who initiate dialysis in an optimal start dialysis group and a late start dialysis group, based on DIFE.

1
2
3
4 **Methods and analysis** A total of 388 enrolled patients with end-stage renal disease
5 (ESRD) will be randomized 1:1 to the optimal start group, with a DIFE value between
6 30 and 35, or the late start dialysis group, with a DIFE value less than 30, using the
7 Randomization and Trial Supply Management (RTSM) system. Participants will be
8 assessed for changes in signs and symptoms, dialysis mode and parameters,
9 biochemical and inflammatory markers, Subjective Global Assessment (SGA),
10 Kidney Disease Quality of Life Short Form (KDQOL-SF™), Cognitive Assessment
11 (MoCA), Medical costs, adverse events, and concomitant medication at baseline,
12 pre-dialysis visiting stage and post-dialysis visiting stage, every 12 to 24 weeks. The
13 following data will be recorded on standardized online electronic case report forms
14 (eCRFs). The primary endpoint is 3-year all-cause mortality. The secondary endpoints
15 include non-fatal cerebro-cardiovascular events, annual hospitalization rate, quality of
16 life, medical costs, and hemodialysis related complications.
17
18

19 **Ethics and dissemination** Ethical approval was obtained from the Ethics Committee
20 of the First Affiliated Hospital of Dalian Medical University China (Registration No:
21 YJ-KY-2017-119) and the ethics committees of all participating centers.
22

23 The final results of the ADIFE trial will be presented to the study sponsor, clinical
24 researchers, and the patient and public involvement (PPI) reference group. Findings
25 will be disseminated through peer-reviewed journals, Clinical Practice Guidelines,
26 and at scientific meetings.
27

28 **Trial registration number** ClinicalTrial.gov. NCT03385902; Pre-results.
29

30 **Keywords** End-Stage Renal Disease; Hemodialysis; Timing of Dialysis Initiation;
31 Fuzzy mathematics.
32

33 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

34
35 ▶ We established a novel and quantifiable equation (DIFE), containing nine
36 laboratory and clinical parameters that together influence the timing of dialysis
37 initiation, which showed significant advantages to assess the timing of dialysis
38 initiation compared with the estimated glomerular filtration rate alone.
39

40 ▶ This is the first prospective, randomized controlled study to assess the timing of
41 initiation of dialysis based on DIFE in patients with ESRD.
42

1
2
3
4 ▶ The study will provide acceptability and feasibility data for optimal dialysis
5 initiation based on DIFE to avoid early and late start dialysis in patients with ESRD.

6
7 ▶ Participants will be recruited from 25 hemodialysis centers in China, which may
8 introduce sample selection bias.

9
10 ▶ The hemodialysis centers do not all use the same dialyzers to treat the participants.

11 INTRODUCTION

12
13 The growing prevalence and incidence of end-stage renal disease (ESRD) represents a
14 global health challenge.¹ Hemodialysis is the main treatment for patients with ESRD,
15 and its start time has a significant effect on patient survival.²⁻⁴ Late or early start of
16 dialysis can negatively affect the quality of life and survival prognosis of patients, and
17 this sub-optimal timing of dialysis results in an increased economic burden for
18 families and society.⁵⁻⁷ Therefore, determining and implementing the optimal time to
19 commence dialysis could improve a patient's quality of life by relieving their uremic
20 symptoms, decreasing their risk of early death, and by reducing medical care costs.⁴
21 However, there is still no consensus on the optimal timing of dialysis initiation for
22 patients with ESRD, and it is unknown what is exactly the optimal timing of dialysis
23 is associated with better outcomes. Several observational studies found that an earlier
24 start of dialysis was associated with improved survival and better prognosis.^{5,8,9}
25 However, certain cohort studies and a randomized controlled trial (the Initiating
26 Dialysis Early and Late (IDEAL) study) have shown that patients receiving early
27 initiation of dialysis were at risk of poor survival and that late initiation of dialysis
28 was associated with lower risk of mortality and improved survival.¹⁰⁻¹³ However,
29 these findings are controversial mainly because of the inefficient or outdated methods
30 of assessing dialysis timing used. All of the above studies used the creatinine-based
31 estimated glomerular filtration rate (eGFR), a value whose specificity is affected by
32 nutritional status and muscle mass, and is calculated by either the Modified Diet in
33 Renal Disease equation or the Cockcroft–Gault equation.^{14,15} Studies have shown that
34 some clinical factors, such as older age, volume overload, malnutrition, diabetes, and
35 heart failure, strongly influence the timing of dialysis initiation.^{5,16-18} Therefore, the
36 Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Hemodialysis Adequacy recommend that the decision to initiate maintenance dialysis
5 should be based primarily on the assessment of specific complications of kidney
6 disease, including signs and symptoms of uremia, protein-energy wasting, metabolic
7 abnormalities, and volume overload, rather than based on the eGFR alone.^{19,20}
8
9 Deviation from an empirical decision to an assessment of varying clinical conditions
10 inevitably leads to a lack of consensus because of clinicians' subjective judgments,
11 which can lead to a sub-optimal decision regarding early or late initiation of dialysis.
12
13
14
15
16

17 Thus, our research team established a novel equation to determine the optimal
18 timing, called dialysis initiation based on a Fuzzy mathematical method (DIFE),
19 which was derived from a previous multicenter, retrospective cohort study with
20 large-scale samples.²¹ The DIFE includes nine parameters: Sex, age, blood urea
21 nitrogen, serum creatinine, hemoglobin, serum albumin, serum phosphorus, heart
22 failure condition, and diabetes condition, which effectively combines subjective
23 clinical variables with objective biochemical markers for dialysis initiation decision
24 making. The DIFE study showed that the 3-year dialysis mortality of patients in the
25 optimal start group (DIFE value of 30 to 35) was markedly lower (8.38%) than the
26 late start group (DIFE value less than 30) of 19.4%. Moreover, receiver operating
27 characteristic (ROC) curve analysis indicated that the area under the curve (AUC) for
28 the prediction of 3-year death during dialysis initiation assessed by the DIFE was
29 significantly higher than that predicted by eGFR (0.70 vs. 0.55, $P < 0.01$).²¹
30 Therefore, the DIFE is more accurate and effective to assess the timing of
31 hemodialysis initiation than eGFR alone. Furthermore, the DIFE equation is
32 convenient for popularization and application because it transforms subjective clinical
33 factors into objective parameters, which will be especially appealing to
34 non-nephrologists and doctors in primary hospitals. DIFE may become the new
35 standard in the assessment of the timing of dialysis, replacing eGFR. To further
36 evaluate the predictive ability and clinical accuracy of DIFE, we designed a
37 prospective, multicenter randomized controlled trial, involving 25 hospitals located in
38 different regions in China, to assess clinical outcomes of patients with ESRD placed
39 in optimal or late start dialysis cohorts on the basis of DIFE. The aims of the trial are
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 to assess the effect of the optimal and late start dialysis, based on DIFE, using the
5
6 3-year mortality rate, hospitalization, morbidity, quality of life, and medical costs of
7
8 patients receiving hemodialysis. We believe that the assessment of DIFE (ADIFE)
9
10 study will provide clinical evidence for the optimal time to start dialysis in patients
11
12 with ESRD based on DIFE.

13 **METHODS AND ANALYSIS**

14 **Study design**

15
16
17 The ADIFE study is a prospective, multicenter, randomized, controlled, open-label
18
19 trial in patients with ESRD. Patients will be divided into an ‘optimal start dialysis’
20
21 group, with DIFE value between 30 and 35, and a ‘late start dialysis’ group, with a
22
23 DIFE value less than 30. The study will be implemented in 25 dialysis centers,
24
25 covering the seven administrative regions in China (North China, East China, South
26
27 Central, Northeast, Southwest, and Northwest). Each participating center has a
28
29 systemic follow-up procedure for the participants with chronic kidney disease and can
30
31 provide predialysis care including preparation of vascular access in patients
32
33 approaching hemodialysis.

34
35 Participants will be followed up at baseline, at the pre-dialysis visiting stage
36
37 every 12 weeks, and at the post-dialysis visiting stage every 12 or 24 weeks. A flow
38
39 diagram of the whole trial is shown in Figure 1. The protocol of the ADIFE study was
40
41 designed according to the SPIRIT reporting guidelines.²²

42 **Participants**

43 **Inclusion criteria**

44
45 Participants will be enrolled the study if they meet all the following requirements:

- 46
47 a. Adults age between 18 to 75 years old;
- 48
49 b. Chronic kidney disease with an eGFR (calculated by the Chronic Kidney Disease
50
51 Epidemiology Collaboration (CKD-EPI) equation²³) of less than 15 mL/min/1.73
52
53 m² and a DIFE value between 30 and 35;
- 54
55 c. Expected to commence maintenance hemodialysis;
- 56
57 d. Agreeable to randomization.

58 **Exclusion criteria**

1
2
3
4 Participants will be excluded if they meet one of the following items:

- 5 a. Acute kidney injury (AKI) or AKI on chronic kidney diseases (CKD);
6
7 b. Having a primary disease comprising systemic lupus erythematosus (SLE) or
8 systemic vasculitis;
9
10 c. Have received, or are planning to receive, a kidney transplantation or peritoneal
11 dialysis;
12
13 d. Recently diagnosed cancer that is likely to impact on survival (except for cured
14 cancer or cancer in remission for over 5 years, after radical resection of the basal
15 cell carcinoma or squamous carcinoma of skin or carcinoma in-situ of any part of
16 the body);
17
18 e. Hepatocirrhosis;
19
20 f. Positive test for Human Immunodeficiency Virus (HIV), hepatitis B virus antigen
21 (HBsAg), or anti-hepatitis C virus antibody (HCVAb);
22
23 g. Acute infectious disease within 1 month;
24
25 h. Poor lifestyle choice that is difficult to withdraw from, such as alcohol abuse;
26
27 i. Poor compliance;
28
29 j. Being pregnant, nursing, or planning for pregnancy;
30
31 k. Life expectancy less than 1 year;
32
33 l. Other cases in which the investigator confirms that they should not enroll in the
34 study.
35
36
37
38
39
40
41

42 **Sample size**

43
44 The sample size estimate is mainly based on the primary endpoint of the 3-year
45 all-cause mortality from the previous retrospective cohort DIFE study, which showed
46 that the 3-year mortality of the optimal start group was 8.38% and that of the late start
47 group was 19.4%.²¹ Using PASS Version 15 of the Power and Sample Size
48 Calculation program (NCSS, LLC, Kaysville, Utah, USA), we estimated a sample
49 size of 154 per group (assuming a type I error rate of 5% with 80% power, two-sided
50 test, with $P < 0.05$ considered statistically significant). Assuming that 20% of the
51 participants would withdraw or drop out, the target sample size was estimated as 388
52 participants, meaning that 194 participants in each group will be recruited.
53
54
55
56
57
58
59
60

Randomization and allocation

Independent biostatisticians with no relationship to the data management or the data statistical analysis team will use the SAS 9.2 software (version 9.1.3; SAS Institute, Inc., Cary, NC, USA) stratified by site to generate random numbers according to the block randomization method. The investigators will allocate the random numbers to eligible participants, assigned 1:1 to the optimal start dialysis group or the late start dialysis group, according to the enrollment sequence. Randomization allocation and random numbers will be sent by automated email to the non-blind investigators performing the randomization using their unique user name and password on the internet-based randomization service of a Randomization and Trial Supply Management system.

Patient and Public Involvement

A patient and public involvement (PPI) reference group, comprising dialysis patients, their partners, carers, and representatives from voluntary sectors, will be formed. The PPI reference group will meet quarterly throughout the duration of the program. Group members have been consulted at all stages of the work leading to this proposal, and have provided valuable insight and advice. The trial was designed in partnership with the PPI to help maximize patient benefits. Our PPI representatives have materially influenced decisions on the study population, promotion, and recruitment. They will also continue to contribute throughout this pilot study in terms of reviewing documentation for ethics approval, reading reports, and contributing to dissemination activities. We will also present the final results of the ADIFE trial to the PPI.

Treatment

All participants will receive regular treatment as usual, which includes regular dietary advice, anemia and Chronic Kidney Disease-Mineral and Bone Disorder management, blood pressure, and volume control, as recommended by the KDIGO guidelines and the Chinese Hemodialysis Adequacy guidelines.^{19,24-27} Different types of vascular access, including temporary venous catheters, arteriovenous fistulas, and artificial blood vessels are permitted for use in all participants. The use of such catheters will be based only on clinical requirements. Each participating center has

1
2
3
4 been advised to consider early access creation in each participant to avoid delay in the
5
6 subsequent hemodialysis treatment.

7
8 All participants will undergo hemodialysis treatment using capacity control
9
10 dialysis machines, bicarbonate dialysate, a blood flow volume of 200–300 mL/min,
11
12 and a disposable high-flux or low-flux dialyzer with membrane area of 1.3–1.6 m².
13
14 The dialysis dose is 4 hours per treatment, performed 2 or 3 times per week; and the
15
16 recommended single pool Kt/V (spKt/V) is more than 1.2.^{19,27,28} However, despite the
17
18 existence of dialysis management guidelines in China, there is still a potential for
19
20 treatment variation between the participating centers.

21 **Intervention**

22
23 Participants allocated to the ‘optimal start dialysis’ group will commence dialysis
24
25 when their DIFE values are between 30 and 35. Participants allocated to the ‘late start
26
27 dialysis’ group will be monitored based on the changes in DIFE values in the
28
29 pre-dialysis visiting stage every 12 weeks until their DIFE values are less than 30, and
30
31 then dialysis will commence. Participants allocated to the ‘late start dialysis’ group
32
33 will be able to commence dialysis earlier based on the recommendation of their caring
34
35 physician, although they should have a DIFE value of no less than 30. For instance,
36
37 participants showing obvious uremia symptoms, volume overload, and hyperkalemia,
38
39 for which the reasons for early initiation of dialysis will be recorded; this will allow
40
41 for a subsequent analysis of actual DIFE at the dialysis start time.

42 **Outcome measurement**

43
44 All enrolled participants will be followed up until death or until 144 weeks after the
45
46 last patient is randomized. Participants in the ‘late start dialysis’ group will be
47
48 assessed every 12 weeks in the pre-dialysis visiting stage. During the post-dialysis
49
50 visiting period, data will be collected every 12 weeks in the first year of follow-up and
51
52 every 24 weeks in the next two years of follow-up. The detailed follow-up items in
53
54 different visiting stage are shown in table 1.

55
56 Comprehensive demographic data (age, gender, ethnicity, height, weight,
57
58 education, employment, causes of ESRD, medical history, presence of comorbid
59
60 conditions) will be collected for all participants at baseline. Virology examination

(Hepatitis B virus antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis antibody) and human urine chorionic gonadotropin (HCG) will be tested in the screening stage. Vital signs, including temperature (T), heart rate (HR), respiratory rate (RR), and non-invasive blood pressure (BP) will be monitored at each follow-up. Biochemical indexes, including blood cell count (red blood cells, white blood cells, and platelets), hemoglobin (Hb), blood urea nitrogen (BUN), serum creatinine (Scr), eGFR, electrolytes (serum sodium, serum potassium, serum chloride, serum calcium, and serum phosphate), alanine transaminase (ALT), glutamic-oxaloacetic transaminase (AST), total bilirubin (T-BIL), blood glucose, serum lipid, serum iron, parathyroid hormone (PTH), and ferritin will be tested every 12–24 weeks in each participating center. Inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, IL-10, tumor necrosis factor- α (TNF- α), and β_2 -microglobulin (β_2 -MG), will be tested every 24 weeks by the central laboratory in the Kidney Disease Research Institute of Dalian Medical University. Nutritional status, assessed using Subjective Global Assessment (SGA),²⁹ and the serum albumin level, will be assessed every 24 weeks. Quality of life will be measured using the well-validated Kidney Disease Quality of Life Short Form™ (KDQOL-SF™)^{30,31} every 48 weeks; and cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA)³² every 24 weeks. The use of concomitant medications, including calcium channel blockers (CCB), statins, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and erythropoiesis stimulating agents (ESAs) will be recorded at baseline and during the follow-up period. Medical costs will be recorded in the pre-dialysis visiting stage and post-dialysis visiting stage using both the questionnaire and medical insurance records of the participants, including dialysis-related costs, hospitalization-related costs, and outpatient costs of comorbidities treatment.

All the above-mentioned data will be recorded on standardized online electronic case report forms (eCRFs) based on an electronic data acquisition system. All adverse events (AEs) will be recorded on the eCRFs on specific pages reserved for this purpose. Serious adverse events (SAEs) are defined as death, life-threatening illness,

hospitalization (or prolongation of initial hospitalization), causing disability or permanent damage, a congenital anomaly, or a birth defect. Completed eCRFs will be entered into a secured central database for independent quality control and centralized analysis.

Table 1 The Follow-up items in different visiting stage of ADIFE study

Follow-up items	Screening stage	Pre-dialysis visiting stage	Post-dialysis visiting stage
			V0–V8 (0–144w)
Signed informed consent form	√	-	-
Inclusion and exclusion criteria	√	-	-
Demographic data	√	-	-
Vital signs, physical examination	√	√	√ (V0–V8)
Urine HCG	√	-	-
Virology examination	√	-	-
Blood routine test	√	√	√ (V0–V8)
BUN, Scr, eGFR, Alb, Electrolytes,	√	√	√ (V0–V8)
ALT, AST, T-BIL, Blood glucose, Serum lipid, serum iron	-	-	√ (V0, V4, V6, V8)
PTH, Ferritin	-	-	√ (V0, V2, V4–V8)
Hs-CRP, IL-6, IL-10, TNF- α , β_2 -MG	-	-	√ (V0, V2, V4–V8)
KDQoL-SF	-	-	√ (V0, V4, V6, V8)
MoCA	-	-	√ (V0, V2, V4–V8)
SGA	-	-	√ (V0, V2, V4–V8)
Vascular access	-	-	√ (V0–V8)
Medical costs	-	√	√ (V0–V8)
Complications related to dialysis	-	-	√ (V0–V8)
AEs, SAEs	-	√	√ (V0–V8)
Concomitant medications	-	√	√ (V0–V8)

Note: ‘√’ represent selected follow-up items; ‘-’ represent not-selected follow-up items.

HCG, human chorionic gonadotropin; BUN, blood urea nitrogen; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; ALB, albumin; ALT, alanine transaminase; AST, glutamic-oxaloacetic transaminase; T-BIL, total bilirubin; PTH, parathyroid hormone; hs-CRP, high sensitive C-reactive protein; IL, interleukin; TNF- α , tumor necrosis factor- α ;

1
2
3
4 β_2 -MG, β_2 -microglobulin; KDQOL-SF, Kidney Disease Quality of Life Short Form; MoCA,
5 Montreal Cognitive Assessment; SGA, subjective global assessment; AEs, adverse events;
6
7 SAEs, serious adverse events.
8

9 **Endpoint measurements**

10
11 The primary endpoint is the 3-year all-cause mortality following randomization to the
12 ‘optimal start dialysis’ or ‘late start dialysis’ groups. Secondary endpoints include
13 cerebro-cardiovascular events (non-fatal myocardial infarction, non-fatal stroke,
14 transient ischemic attack, new-onset angina, acute heart failure, or severe arrhythmia
15 requiring hospitalization), infectious complications, hemodialysis complications
16 (including changes of vascular access, vascular access related infection, fluid and
17 electrolyte disorders, and cognitive dysfunction), annual hospitalization (proportion of
18 participants admitted to hospital every year), quality of life, nutrition assessment,
19 cognitive dysfunction, and medical costs.
20
21
22
23
24
25
26
27
28

29 **Statistical analysis**

30
31 For all baseline and outcome variables, the number of available measurements and the
32 number of missing values will be recorded. All analyses will be conducted according
33 to the intention-to-treat (ITT) principle,³³ that is, all randomized patients will be
34 analyzed in the groups to which they were originally allocated, and noncompliance
35 with treatment and other violations of the protocol will be measured and reported as
36 an ITT effect estimate. We also will perform inverse probability weighting (IPW) to
37 adjust the selection bias due to attrition.³⁴ Continuous variables will be checked for
38 normal distribution and will be presented as the mean and SD or median and
39 interquartile range (IQR) as appropriate. Comparisons of continuous variables will be
40 performed using Student’s t test for normally distributed variables and the
41 Mann–Whitney U test for non-normally distributed variables. Categorical variables
42 will be presented as numbers and percentages, and analyzed using the Chi-squared
43 test. The primary outcome of 3-year all-cause mortality will be compared between the
44 optimal start and late start groups using the Cochran–Mantel–Haenszel procedure,
45 adjusting for center. A logistics regression model will be performed to adjust for
46 potential confounders, such as age, sex, body mass index (BMI), urine volume, SGA,
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 blood urea nitrogen, serum creatinine, hemoglobin, serum albumin, serum phosphorus,
5 PTH, Ferritin, Hs-CRP, IL-6, IL-10, TNF- α , β_2 -MG, cause of ESRD, vascular access,
6 comorbidity, complication of dialysis, and dialysis mode. All analyses will be
7 performed using SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA) by the team of
8 statisticians at the Fuwai Hospital, China. All reported *P* values will be two-sided and
9 *P* values less than 0.05 will be considered significant.

15 **ETHICS AND DISSEMINATION**

17 **Ethics**

19 Ethical approval was obtained from the ethics committees of the First Affiliated
20 Hospital of Dalian Medical University (Registration No: YJ-KY-2017-119) and the
21 ethics committees of all participating centers (see supplementary file).

25 **Informed consent and withdrawal from the study**

27 Each participant or their authorized surrogates will sign an informed consent form.
28 The process of informed consent will be in accordance with the Declaration of
29 Helsinki. Participants will be fully informed about the ADIFE study by the
30 investigators, and will be able to discuss the trial process with their nephrologists and
31 contact the investigator directly to request further information. Participants and
32 authorized surrogates will receive the related materials of informed consent.
33 Participants will be informed of their right to withdraw from the study, either at their
34 own request or at the discretion of the investigator, at any time without their care
35 being affected in any way.

44 **Dissemination plan**

46 Survey data will be exported directly from the eCRFs as a text file and imported in
47 electronic form for scoring and analysis using statistics software. A detailed database
48 will track participants' progress through the trial, including the scheduling of
49 assessments and reminders to complete assessments. Detailed strategies, including
50 phone or text message reminders, will be used to remind participants about upcoming
51 assessments. All members of the research team and other associated personnel will
52 have access to the final trial dataset in both identified and re-identifiable forms.

58 Printed data will be stored in locked filing cabinets, accessible only to the
59

1
2
3
4 research team. Electronic data will be stored on password-protected computers or
5 servers that are only accessible to the research team. All paper and electronic records
6 will be retained and disposed of in accordance with the requirements of the Criteria
7 for the Quality Control of Clinical Trial from Drugs China Food and Drug
8 Administration (CFDA).
9
10
11
12

13 The results from the outcome measures will not be presented in a way that
14 compromises the confidentiality of the participants. Descriptions of participants will
15 not allow identification of individual participants, and individual results and
16 individual names will not be revealed. Final reports and publications will only
17 comprise aggregated results. At completion of the study, participants will receive a
18 plain text summary of the study results in Chinese. Scientific reports of the main
19 outcomes, secondary outcomes, and process evaluation will be submitted to an
20 international peer-reviewed journal. The results will also be presented at national and
21 international conferences relevant to the subject fields.
22
23
24
25
26
27
28
29

30 **Data management**

31 All information concerning the participants will be recorded on standardized online
32 eCRFs, which will be anonymized and saved on password-protected computers. The
33 data monitoring committee (DMC), which will be independent from the sponsor and
34 any other competing interests, will meet twice yearly to review the efficacy and safety
35 data.
36
37
38
39
40
41

42 **Oversight committees**

43 A Trial Steering Committee has been set-up and will include an independent
44 chairperson, 25 independent members, and the study investigators.
45
46
47

48 **Safety monitoring**

49 AEs will be closely monitored. These are events that are likely to affect the safety or
50 physical or mental integrity of the participants in the trial to a significant degree.
51 SAEs must be reported to the sponsor (the First Affiliated Hospital of Dalian Medical
52 University, China) and the State Food and Drug Administration promptly, by fax or
53 telephone, by the investigators, followed by a written report within 24 hours. The
54 sponsor will be notified immediately of any case where the above definition applies
55
56
57
58
59
60

1
2
3 during the trial.

4 5 **DISCUSSION**

6
7 The timing of dialysis initiation is a risk factor that affects the prognosis of patients
8 with ESRD. However, the optimal timing of dialysis initiation remains unclear. Some
9 studies showed that an early start of dialysis was associated with a lower risk of
10 mortality,⁵ whereas others studies indicated either a survival advantage of late start
11 dialysis^{3,11,12,35} or comparable mortality risk between early and late start dialysis.^{36,37}
12 The IDEAL study indicated that using eGFR as the primary guide for when to start
13 dialysis should probably be abandoned in a patient with progressive advanced CKD.¹⁰
14
15
16
17
18
19
20

21 The novel DIFE score integrates subjective clinical variables of uremic signs and
22 symptoms with objective biochemical markers beyond serum creatinine and eGFR to
23 assess the timing of dialysis initiation in patients with ESRD, providing an
24 individualized, effective, and convenient tool for dialysis initiation decision-making.
25 The results of ADIFE study will provide evidence to evaluate the accuracy and
26 efficacy of DIFE and should indicate optimal timing of dialysis initiation for patients
27 with ESRD approaching the need for maintenance dialysis. For some nephrologists
28 and non-nephrologists with less training who may not know how to interpret
29 laboratory values and clinical signs, a formula to calculate when to start dialysis could
30 help them to deliver safe care.
31
32
33
34
35
36
37
38
39

40 The DIFE formula was established via a previous retrospective multicenter
41 cohort study using data from patients receiving hemodialysis, and the ADIFE study
42 will further assess the clinical accuracy and applicability of DIFE to guide the timing
43 of hemodialysis initiation. Therefore, the ADIFE study will exclude participants
44 awaiting peritoneal dialysis and transplantation; however, we have already planned to
45 assess the applicability of DIFE to guide the timing of dialysis for patients undergoing
46 peritoneal dialysis in another clinical study.
47
48
49
50
51
52
53

54 **Author contributions**

55 All authors meet the ICMJE criteria for authorship in that they have contributed
56 substantially to the conceptual design or the processes of data collection, analysis, or
57 interpretation, the drafts and revisions of the study protocol and manuscript, granted
58
59
60

1
2
3 approval of the final version of the study protocol, and acknowledged their
4 accountability with regard to the integrity and accuracy of this study protocol.
5

6
7 Research idea and study design: Hongli Lin, Xiangmei Chen, Xuefeng Sun, Ximing
8 Sun, Degang Wang, Ming Fang, and Lynda Szczech.
9

10
11 Writing and reviewing of the protocol: Jilin Chen, Ying Liu, Hongli Lin, Ping Li, and
12 Yang Wang.
13

14
15 Drafting of the manuscript: Jilin Chen, Ying Liu, and Zach Odeh will be responsible
16 for administrative and managerial procedures related to all phases of the trial, which
17 will be supervised by Hongli Lin.
18

19
20 Statistical analysis: Yang Wang, and Wei Li.
21

22
23 Discussion of the protocol or participant enrollment or follow up-related work: Jilin
24 Chen, Ying Liu, Hongli Lin, Hongli Jiang, Wei Shi, Wenhui Liu, Ping Fu, Xiaoqiang
25 Ding, Ming Chang, Shuxin Liu, Xiao Yang, Ning Cao, Menghua Chen, Zhaohui Ni,
26 Jing Chen, Shiren Sun, Xinling Liang, Huimin Wang, Yani He, Bihu Gao, Jianqin
27 Wang, Lirong Hao, Jian Liu, Suhua Li, Qiang He, Hongmei Liu, Na Yi, Fengmin
28 Shao, Jundong Jiao, Yuhuan Ma, Li Yao, Yi Sun and Detian Li.
29
30
31
32
33

34 35 **Trial status**

36
37 Recruitment has commenced using digital social media networks and print-based
38 advertising nationwide in April 2018. Completion of recruitment is expected in April
39 2020. The study will be completed by December 2023.
40

41 42 **Acknowledgements**

43
44 The authors thank all staff for their support with this study and the members of the
45 patient and public involvement group for their invaluable advice. We acknowledge
46 Dr. Mark Roger Marshall (Associate Professor of University of Auckland, New
47 Zealand) for his expert guidance and helpful comments on the study design.
48
49

50 51 **Funding**

52
53 The ADIFE study is an investigator-initiated and conducted study. This work is
54 supported by the special fund for National Health and Family Planning Commission
55 (NHFPC) Scientific Research in the Public Welfare (grant number 201502023).
56
57

58
59 The NHFPC will have no role in the design, conduct, management, analysis, or
60

1
2
3
4 interpretation of the study.

5 **Conflicts of interests** None.

6
7 **References**

- 8
9
10 1. Woo KT, Choong HL, Wong KS, *et al.* The contribution of chronic kidney disease to the global
11 burden of major noncommunicable diseases. *Kidney Int* 2012; 81: 1044-5.
12 2. Feng L, Jin AZ, Allen JC, *et al.* Timing of commencement of maintenance dialysis and mortality in
13 young and older adults in Singapore. *BMC Nephrol* 2017; 18: 176.
14 3. Park JY, Yoo KD, Kim YC, *et al.* Early dialysis initiation does not improve clinical outcomes in elderly
15 end-stage renal disease patients: A multicenter prospective cohort study. *PLoS One* 2017; 12:
16 e0175830.
17 4. Mehrotra R, Rivara M, Himmelfarb J. Initiation of dialysis should be timely: neither early nor late.
18 *Semin Dial* 2013; 26: 644-9.
19 5. Churchill DN. An evidence-based approach to earlier initiation of dialysis. *Am J Kidney Dis* 1997; 30:
20 899-906.
21 6. Traynor JP, Simpson K, Geddes CC, *et al.* Early initiation of dialysis fails to prolong survival in
22 patients with end-stage renal failure. *J Am Soc Nephrol* 2002; 13: 2125-32.
23 7. Faust J, Schreiner O. Early versus late initiation of dialysis. *N Engl J Med* 2010; 363: 2368-9; author
24 reply 9-70.
25 8. Wingard RL, Pupim LB, Krishnan M, *et al.* Early intervention improves mortality and hospitalization
26 rates in incident hemodialysis patients: RightStart program. *Clin J Am Soc Nephrol* 2007; 2: 1170-5.
27 9. Korevaar JC, Jansen MA, Dekker FW, *et al.* When to initiate dialysis: effect of proposed US
28 guidelines on survival. *Lancet* 2001; 358: 1046-50.
29 10. Cooper BA, Branley P, Bulfone L, *et al.* A randomized, controlled trial of early versus late initiation
30 of dialysis. *N Engl J Med* 2010; 363: 609-19.
31 11. Wright S, Klausner D, Baird B, *et al.* Timing of dialysis initiation and survival in ESRD. *Clin J Am Soc*
32 *Nephrol*, 2010; 5: 1828-35.
33 12. Hwang SJ, Yang WC, Lin MY, *et al.* Impact of the clinical conditions at dialysis initiation on
34 mortality in incident haemodialysis patients: a national cohort study in Taiwan. *Nephrol Dial*
35 *Transplant* 2010; 25: 2616-24.
36 13. Susantitaphong P, Altamimi S, Ashkar M, *et al.* GFR at initiation of dialysis and mortality in CKD: a
37 meta-analysis. *Am J Kidney Dis* 2012; 59: 829-40.
38 14. Zaman T, Filipowicz R, Beddhu S. Implications and importance of skeletal muscle mass in
39 estimating glomerular filtration rate at dialysis initiation. *J Ren Nutr* 2013; 23: 233-6.
40 15. Escoli R, Luz I, Santos P, *et al.* Glomerular Filtration Rate and Initiation of Dialysis. *Ther Apher Dial*
41 2017; 21: 606-10.
42 16. Lin X, Zeng XZ, Ai J. The Glomerular Filtration Rate (GFR) at Dialysis Initiation and Mortality in
43 Chronic Kidney Disease (CKD) in East Asian Populations: A Meta-analysis. *Intern Med* 2016; 55:
44 3097-104.
45 17. Lassalle M, Labeeuw M, Frimat L, *et al.* Age and comorbidity may explain the paradoxical
46 association of an early dialysis start with poor survival. *Kidney Int* 2010; 77: 700-7.
47 18. Brown MA, Collett GK, Josland EA, *et al.* CKD in elderly patients managed without dialysis: survival,
48 symptoms, and quality of life. *Clin J Am Soc Nephrol* 2015; 10: 260-8.
49 19. National Kidney F. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. *Am*
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

J Kidney Dis 2015; 66: 884-930.

20. Grootendorst DC, Michels WM, Richardson JD, *et al.* The MDRD formula does not reflect GFR in ESRD patients. *Nephrol Dial Transplant* 2011; 26: 1932-7.

21. Liu Y, Wang D, Chen X, *et al.* An Equation Based on Fuzzy Mathematics to Assess the Timing of Haemodialysis Initiation. *Sci Rep* 2019; 9: 5871.

22. Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 Statement: defining standard protocol items for clinical trials. *Rev Panam Salud Publica* 2015; 38: 506-14.

23. Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150: 604-12.

24. Taler SJ, Agarwal R, Bakris GL, *et al.* KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. *Am J Kidney Dis* 2013; 62: 201-13.

25. Klinger AS, Foley RN, Goldfarb DS, *et al.* KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *Am J Kidney Dis* 2013; 62: 849-59.

26. Isakova T, Nickolas TL, Denburg M, *et al.* KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Am J Kidney Dis* 2017; 70: 737-51.

27. Group CNAHAC. Clinical practice guide for Chinese hemodialysis adequacy. *Natl Med J China* 2015; 95: 2748-53.

28. Chen XM, Ding XQ, Liu FY, *et al.* Blood Purification Standard Operating Procedure(SOP):2010 version, 2010.

29. Raguso CA, Maisonneuve N, Pichard C. [Subjective Global Assessment (SGA): evaluation and followup of nutritional state]. *Rev Med Suisse Romande* 2004; 124: 607-10.

30. Hays RD, Kallich JD, Mapes DL, *et al.* Development of the kidney disease quality of life (KDQOL) instrument. *Qual Life Res* 1994; 3: 329-38.

31. Hays RD KJ, Mapes D, Coons S, *et al.* Kidney Disease Quality of Life Short Form (KDQOL-SF™), Version 1.3: A Manual for Use and Scoring.

32. Nasreddine ZS, Phillips NA, Bedirian V, *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695-9.

33. Mansournia MA, Higgins JP, Sterne JA, *et al.* Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. *Epidemiology* 2017; 28: 54-9.

34. Mansournia MA, Altman DG. Inverse probability weighting. *BMJ* 2016;352: i189.


35. Pan Y, Xu XD, Guo LL, *et al.* Association of early versus late initiation of dialysis with mortality: systematic review and meta-analysis. *Nephron Clin Pract* 2012; 120: c121-31.

36. Yamagata K, Nakai S, Iseki K, *et al.* Late dialysis start did not affect long-term outcome in Japanese dialysis patients: long-term prognosis from Japanese Society for [corrected] Dialysis Therapy Registry. *Ther Apher Dial* 2012; 16: 111-20.

37. Scialla JJ, Liu J, Crews DC, *et al.* An instrumental variable approach finds no associated harm or benefit with early dialysis initiation in the United States. *Kidney Int* 2014; 86: 798-809.

Figure legends

Figure 1 **Trial Flow Diagram of the ADIFE study.** The whole trial flow, including the screening stage within seven days, pre-dialysis visiting stage, and post-dialysis visiting stage of visit 0 to visit 8. Enrolled subjects will be randomized 1:1 to the optimal start dialysis group with a DIFE value between 30 and 35 or to the late start dialysis group with a DIFE value less than 30. Participants will be followed up at baseline (visit 0), pre-dialysis visiting stage every 12 weeks, and post-dialysis visiting stage every 12 or 24 weeks. ESRD, End-Stage Renal Disease; DIFE, Dialysis Initiation based on Fuzzy-mathematics Equation.



Trial Flow Diagram of the ADIFE study

90x40mm (300 x 300 DPI)

The ethics committees of all participating centers

The ethics committees of the First Affiliated Hospital of Dalian Medical University (Registration No: YJ-KY-2017-119) .

The ethics committees of the Chinese PLA General Hospital (Registration No: S2018-021-01).

The ethics committees of the first Affiliated Hospital of Xi'an Jiaotong University (Registration No: XJTU1AF2018LSK-05).

Research Ethics Committee of Guangdong General Hospital, Guangdong Academy of Medical Sciences (Registration No: GDREC2018001H [R1]).

The ethics committees of the Beijing Friendship Hospital, Capital Medical University (Registration No: 2018-P2-013-02).

The ethics committees of the West China Hospital of Sichuan University (Registration No: 2018[39]).

The ethics committees of the Zhongshan Hospital, Fudan University (Registration No: B2018-109R).

The ethics committees of the Dalian Municipal Central Hospital (Registration No: 2018-051-01).

ICE for Clinical Research and Animal Trials of the First Affiliated Hospital, Sun Yat-sen University (Registration No:[2018]021).

The ethics committees of the General Hospital of Ningxia Medical University (Registration No: 2018-137).

Renji Hospital Ethics Committee of Shanghai Jiaotong University School of Medicine (Registration No: [2017]239).

The ethics committees of the Huashan Hospital, Fudan University (Registration No:[2018]013).

The ethics committees of the Xijing Hospital, The Fourth Military Medical University (Registration No: KY20182007-1).

1
2
3
4 The ethics committees of the General Hospital of Benxi Iron and Steel Co., Ltd
5
6 (Registration No: No applicable).

7
8 The ethics committees Daping Hospital Affiliated to Army Military Medical University
9
10 (Registration No: [2018]20).

11
12 The ethics committees of Affiliated Zhong Shan Hospital of Dalian University
13
14 (Registration No: 2018-001).

15
16 The ethics committees of Lanzhou University Second Hospital (Registration No:
17
18 2018A-006).

19
20 The ethics committees of the First Affiliated Hospital of Harbin Medical University
21
22 (Registration No: 201811).

23
24 The ethics committees of the First Affiliated Hospital of Xinjiang Medical University
25
26 (Registration No: 20180330-09).

27
28 The ethics committees of the An Steel Group Hospital (Registration No: [2018]3).

29
30 The ethics committees of the Henan Provincial People's Hospital (Registration No:
31
32 [2018]04).

33
34 The ethics committees of the Second Affiliated Hospital of Harbin Medical University
35
36 (Registration No: KY2017-269).

37
38 The ethics committees of the General Hospital of Mining Industry Group FuXin
39
40 (Registration No: Not applicable).

41
42 The ethics committees of the First Hospital of China Medical University (Registration
43
44 No: [2018] 2018-29-2).

45
46 The ethics committees of the Central Hospital Affiliated To Shenyang Medical College
47
48 (Registration No: Not applicable).

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	4
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	17
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1-3,16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	15

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	17
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	15
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5-7
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	5-7
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	6-7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	7-8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	9-10
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	9-12
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	9-10
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	10-13
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	Figure 1
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	8
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	14
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	9
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	9
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	9
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	n/a
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	15
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	15
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	15
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	13
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	13
53	analyses		adjusted analyses)	
54				
55				
56	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	13
57	population and		adherence (eg, as randomised analysis), and any statistical	
58	missing data		methods to handle missing data (eg, multiple imputation)	
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	15
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	15
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	15
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	14
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	14
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	14-15
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	17
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	15
60				

		and disclosure of contractual agreements that limit such access for investigators	
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	14
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)